zzzPrisma Health Labs Reference Ranges

	Performing Lab	PROCEDURE:	REFERENCE:
	Collaboration powered by Smartsheet   |   Report Abuse
1	BCH BPH CI RHC RHR THL	Associated Policy:	Revised: 4/4/2025
2	BCH BPH CI RHC RHR THL	Laboratory General Policy
3	BCH BPH CI RHC RHR THL
4	BCH BPH CI RHC RHR THL	RESPONSIBLE POSITIONS:	.
5	BCH BPH CI RHC RHR THL	1. Laboratory Workforce	.
6	BCH BPH CI RHC RHR THL	2. Prisma Health Providers	.
7	BCH BPH CI RHC RHR THL
8	BCH BEH BPH GMH GrMH HMH LCH NGH OMH PWH RHC RHR THL	CLINICAL LABORATORIES:	.
9	BCH BPH RHC RHR THL	Prisma Health Baptist Columbia Hospital Laboratory Taylor at Marion Street Columbia, SC 29220	Prisma Health Baptist Parkridge Hospital Laboratory 400 Palmetto Health Parkway Columbia, SC 29212
10	BCH BPH RHC RHR THL	Prisma Health Richland Hospital Central Laboratory 14 Richland Medical Park Drive Columbia, SC 29203	Prisma Health Richland Hospital Rapid Laboratory 5 Richland Medical Park Drive Columbia, SC 29203
11	BCH BPH RHC RHR THL	Prisma Health Tuomey Hospital Laboratory 129 North Washington Street Sumter, SC 29150
12	BCH BPH RHC RHR Respiratory THL	Prisma Health Baptist Easley Hospital Laboratory 200 Fleetwood Drive Easley, SC 29640	Prisma Health Greenville Memorial Hospital Laboratory 701 Grove Road Greenville, SC 29605
13	BCH BPH RHC RHR Respiratory THL	Prisma Health Greer Memorial Hospital Laboratory 830 S Buncombe Road Greer, SC 29650	Prisma Health Hillcrest Hospital Laboratory 729 SE Main Street Simpsonville, SC 29681
14	BCH BPH RHC RHR Respiratory THL	Prisma Health Laurens County Hospital Laboratory 22725 US-76 Clinton, SC 29325	Prisma Health North Greenville Hospital Laboratory 807 N Main Street Travelers Rest, SC 29690
15	BCH BPH RHC RHR Respiratory THL	Prisma Health Oconee Memorial Hospital Laboratory 298 Memorial Drive Seneca, SC 29672	Prisma Health Patewood Hospital Laboratory 175 Patewood Drive Greenville, SC 29615
16	Respiratory
17	CI	CANCER INSTITUTE LABORATORIES:	.
18	CI	Prisma Health Cancer Institute – Eastside 65 International Dr. Greenville, SC 29615	Prisma Health Cancer Institute – Faris Road 900 W Faris Rd Greenville, SC 29605
19	CI	Prisma Health Cancer Institute – Greer 340 Medical Pkwy Greer, SC 29650	Prisma Health Cancer Institute – Grove Commons 3 Butternut Dr Suite B Greenville, SC 29605
20	CI	Prisma Health Cancer Institute – Seneca 131 Lila Doyle Dr Seneca, SC 29672	Prisma Health Cancer Institute – Spartanburg 2400 Boiling Springs Rd Spartanburg, SC 29316
21		Prisma Health Cancer Institute – Laurens 22725 Hwy 76 E, 3rd Floor Clinton, SC 29325
22	CI
23	BCH BPH CI RHC RHR THL	PROCEDURE:	REFERENCE:
24	BCH BPH RHR THL	Acetaminophen	10 - 30 ug/mL
25	BCH BPH RHR THL
26	GMH	Adenovirus Rapid	Not Detected
27	GMH
28	BCH BPH RHC GL RHR THL	Albumin	SERUM: 0 - 3 Days: 2.8 - 4.4 g/dL 4 Days - 13 Years: 3.8 - 5.4 g/dL 14 - 18 Years: 3.2 - 4.5 g/dL >/= 19 Years: 3.5 - 5.2 g/dL BODY FLUID: The separation of ascitic fluids into transudates or exudates has been superseded by the division of ascitic fluids into high-gradient or low-gradient fluids as determined by the serum-ascites albumin gradient calculated as (serum albumin) - (ascitic fluid albumin). The gradient is a reflection of the hydrostatic pressure in the portal circulation. Gradients >/=1.1 g/dL are considered high. Specimens of serum and fluid should be drawn the same day. High Values may be seen in: Cirrhosis, Fulminant hepatic failure, Fatty liver, Alcoholic hepatitis, Portal vein thrombosis, Veno-Occlusive disease; Low Values may be seen in Peritoneal carcinomatosis, Tuberculosis, Pancreatic, Connective tissue disease, Nephrotic syndrome, Biliary (without cirrhosis). Pleural Fluid: Serum Albumin Level - Pleural Fluid Albumin Level </= 1.2 g/dL is predictive of an exudate.
29	BCH BPH RHC GL RHR THL
30	CI	Albumin	0 - 11 Months: 2.8 - 4.7 g/dL 1 - 60 Years: 3.5 - 5.0 g/dL >/= 61 Years: 3.4 - 4.8 g/dL
31	CI
32	BCH BPH RHC GL RHR THL	Alcohol, plasma (Medical Only)	< 11 mg/dL
33	BCH BPH RHC GL RHR THL
34	BCH BPH RHC GL RHR THL	Alkaline Phosphatase	Female: 0 - 14 Days: 83 - 248 IU/L 15 Days - 11 Months: 122 - 469 IU/L 1 - 9 Years: 142 - 335 IU/L 10 - 12 Years: 129 - 417 IU/L 13 - 14 Years: 57 - 254 IU/L 15 - 16 Years: 50 - 117 IU/L 17 - 18 Years: 45 - 87 IU/L >/= 19 Years: 35 - 104 IU/L Male: 0 - 14 Days: 83 - 248 IU/L 15 Days - 11 Months: 122 - 469 IU/L 1 - 9 Years: 142 - 335 IU/L 10 - 12 Years: 129 - 417 IU/L 13 - 14 Years: 116 - 468 IU/L 15 - 16 Years: 82 - 331 IU/L 17 - 18 Years: 55 - 149 IU/L >/= 19 Years 40 - 129 IU/L
35	BCH BPH RHC GL RHR THL
36	CI	Alkaline Phosphatase	Female: 0 - 14 Days: 90-273 IU/L 15 Days - 11 Months: 134-518 IU/L 1 - 9 Years: 156-369 IU/L 10 - 12 Years: 141-460 IU/L 13 - 14 Years: 62-280 IU/L 15 - 16 Years: 54-128 IU/L 17 - 18 Years: 48-95 IU/L >/= 19 Years: 40-150 IU/L Male: 0 - 14 Days: 90-273 IU/L 15 Days - 11 Months: 134-518 IU/L 1 - 9 Years: 156-369 IU/L 10 - 12 Years: 141-460 IU/L 13 - 14 Years: 127-517 IU/L 15 - 16 Years: 89-365 IU/L 17 - 18 Years: 59-164 IU/L >/= 19 Years: 40-150 IU/L
37	CI
38	RHC	Alkaline Phosphatase, Fractionated	If total Alkaline Phosphatase is elevated and labile fraction exceeds 70%- consistent with bone origin.
39	RHC
40	RHC	Allergens IgE - Except Peanut Components	< 0.35 kU/L Interpretive Data: Less than 0.10 kU/L - Normal: No significant level detected 0.10 - 0.34 kU/L - For Specialists use only: Clinical relevance undetermined 0.35 - 0.70 kU/L - Low: Indicative of ongoing sensitization 0.71 - 3.50 kU/L - Moderate: Indicative of stronger ongoing sensitization 3.51 - 17.50 kU/L - High: Indicative of high level sensitization 17.51 kU/L or Greater - Very High: Indicative of very high level sensitization
41	RHC
42	RHC	Allergens IgE - Peanut Components	< 0.10 kU/L Interpretive Data: Any detectable level (>/= 0.1 kU/L) of Specific IgE for Peanut Components may be significant. Ara h 1, 2, 3, and 6 are the peanut proteins most linked to systemic allergic reactions, including anaphylaxis. If any one of these four components is positive, the patient has a high risk of systemic allergic reaction when exposed to peanuts, regardless of the whole peanut allergen result. Reactivity to Ara h 9 and non-reactivity to Ara h 1,2,3 and 6 indicates a variable risk of systemic allergic reaction including anaphylaxis. Reactivity to Ara h 8 and Profilin and non-reactivity to Ara h 1,2,3 and 6 indicates a lower risk of a systemic allergic reaction. Reactivity to CCD and non-reactive to Ara h 1,2,3 and 6 indicates lowest risk of a systemic allergic reaction.
43	RHC
44	RHC	Alpha 1 Antitrypsin	90 - 200 mg/dL
45	RHC
46	CI	Alpha Fetoprotein Tumor Marker	Female: 0 - 29 Days: 0.50-18,964.00 ng/mL 1 - 10 Months: 0.50-77.00 ng/mL 11 Months - 2 Years: 0.50-11.10 ng/mL >/= 3 Years: 0.00-9.00 ng/mL Male: 0 - 29 Days: 0.50-16,387.00 ng/mL 1 - 10 Months: 0.50-28.30 ng/mL 11 Months - 2 Years: 0.50-7.90 ng/mL >/= 3 Years: 0.00-9.00 ng/mL
47	CI
48	BCH BPH RHC RHR THL	ALT (SGPT)	Female: 0 - 11 Months: </=25 IU/L 1 - 12 Years: </=19 IU/L 13 - 19 Years: </=17 IU/L >/= 20 Years: 10 - 35 IU/L Male: 0 - 11 Months: </=25 IU/L 1 - 12 Years: </=19 IU/L 13 - 19 Years: </=18 IU/L >/= 20 Years: 10 - 50 IU/L
49	BCH BPH RHC RHR THL
50	CI	ALT (SGPT)	0 - 11 Months: 5-33 IU/L 1 - 13 Years: 9-25 IU/L 13 - 19 Years: Female: 8-22 IU/L Male: 9-24 IU/L >/= 20 Years: <55 IU/L
51	CI
52	RHC	Amikacin	TROUGH: 0 - 2 Months < 5.1 ug/mL >/= 3 Months 4.0 - 8.0 ug/mL PEAK: 25.0 - 35.0 ug/mL RANDOM: 8.0 - 25.0 ug/mL
53	RHC
54	BCH BPH RHC RHR THL	Ammonia, Plasma	Female: 11 - 51 umol/L Male: 16 - 60 umol/L
55	BCH BPH RHC RHR THL
56	BCH BPH RHR THL	Amnisure	Negative
57	BCH BPH RHR THL
58	BCH BPH RHC RHR THL	Amylase	SERUM: 0 - 14 Days: 3 - 11 IU/L 15 - 84 Days: </=26 IU/L 85 Days - 11 Months: 3 - 58 IU/L 1 - 18 Years: 29 - 118 IU/L >/=19 years: 28 - 100 IU/L BODY FLUID: Interpretive Data: Peritoneal: Elevated at very high concentrations in pancreatitis. At least several-fold times higher in fluid of pancreatic origin compared to simultaneous values in serum, even in cases of acute pancreatitis. Elevated in pancreatic injury. Pleural Fluid: May be high due to contamination with salivary secretions and food in suspected esophageal rupture.
59	BCH BPH RHC RHR THL
60	BCH BPH RHC RHR THL	Anion Gap	6 - 16 mmol/L
61	BCH BPH RHC RHR THL
62	RHC	Anti-Streptolysin O (ASO)	0 - 3 Years: < 100 U/mL 4 - 17 Years: < 251 U/mL >/= 18 Years: < 200 U/mL
63	RHC
64	RHC	Anti-Thrombin III Assay (ATIII)	80 - 120 %
65	RHC
66	RHC	APT Fetal Hemoglobin	No fetal hemoglobin
67	RHC
68	BCH BPH RHC RHR THL	AST (SGOT)	Female: 0 - 14 Days: </= 155 IU/L 15 Days - 11 Months: </= 63 IU/L 1 - 6 Years: </= 41 IU/L 7 - 11 Years: </= 33 IU/L 12 - 18 Years: </= 23 IU/L >/= 19 Years: 10 - 35 IU/L Male: 0 - 14 Days: </=155 IU/L 15 Days - 11 Months: </= 63 IU/L 1 - 6 Years: </= 41 IU/L 7 - 11 Years: </= 33 IU/L 12 - 18 Years: </=32 IU/L >/= 19 Years: 10 - 50 IU/L
69	BCH BPH RHC RHR THL
70	CI	AST (SGOT)	0 - 14 Days: Female: 23 - 119 IU/L Male: 23 - 86 IU/L 15 Days - 11 Months: 23 - 83 IU/L >/= 1 Year: 5 - 34 IU/L
71	CI
72	RHC	Beta-2 Glycoprotein Antibodies IgG	< 7.0 U/mL Interpretive Data: < 7.0 Normal 7.0-10.0 Equivocal - Recommend to retest the patient after 4-6 weeks. > 10.0 Positive The expected value in the normal population is negative. However, up to 3% of apparently healthy, asymptomatic individuals may have increased levels of B2-Glycoprotein I antibodies. Anti-B2 Glycoprotein I antibodies may be present in the so called antiphospholipid syndrome, often appearing in conjunction with SLE, and sometimes occurring without symptoms of SLE. Clinical manifestations can be thrombosis, recurrent pregnancy loss, thrombocytopenia, hemolytic anemia, and other features such as livedo reticularis, migraines, epilepsy, and others. A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated. Expected values may vary on the population tested.
73	RHC
74	RHC	Beta-2 Glycoprotein Antibodies IgM	< 7.0 U/mL Interpretive Data: < 7.0 Normal 7.0-10.0 Equivocal - Recommend to retest the patient after 4-6 weeks. > 10.0 Positive The expected value in the normal population is negative. However, up to 3% of apparently healthy, asymptomatic individuals may have increased levels of B2-Glycoprotein I antibodies. Anti-B2 Glycoprotein I antibodies may be present in the so called antiphospholipid syndrome, often appearing in conjunction with SLE, and sometimes occurring without symptoms of SLE. Clinical manifestations can be thrombosis, recurrent pregnancy loss, thrombocytopenia, hemolytic anemia, and other features such as livedo reticularis, migraines, epilepsy, and others. A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated. Expected values may vary on the population tested. Rheumatoid factor (RF) can interfere with the determination of IgM anti B2 Glycoprotein I antibodies.
75	RHC
76	BCH BPH RHC RHR THL	Beta HCG, Quantitative	</= 5 mIU/mL Non Pregnant Premenopausal Women </= 8 mIU/mL Postmenopausal Women </= 2 mIU/mL Male Weeks of gestation: 3: 6-71 mIU/mL 4: 10-750 mIU/mL 5: 217-7138 mIU/mL 6: 158-31795 mIU/mL 7: 3697-163563 mIU/mL 8: 32065-149571 mIU/mL 9: 63803-151410 mIU/mL 10: 46509-186977 mIU/mL 12: 27832-210612 mIU/mL 14: 13950-62530 mIU/mL 15: 12039-70971 mIU/mL 16: 9040-56451 mIU/mL 17: 8175-55868 mIU/mL 18: 8099-58176 mIU/mL
77	BCH BPH RHC RHR THL
78	BCH BPH RHR THL	Beta-Hydroxybutyric Acid	0.0 - 0.5 mmol/L 0.6-1.5 mmol/L w/Glucose >/=300 mg/dL Potential for development of problem requiring medical intervention >1.5 mmol/L w/Glucose >/=300 mg/dL May indicate the risk of developing diabetic ketoacidosis (DKA)
79	BCH BPH RHR THL
80	GMH	Bile Acids	0.0 - 12.0 umol/L
81	GMH
82	BCH BPH RHC RHR THL	Bilirubin, Direct	0 - 14 Days: 0.3 - 0.5 mg/dL 15 Days - 11 Months: </= 0.2 mg/dL 1 - 8 Years: </= 0.1 mg/dL 9 - 12 Years: </=0.2 mg/dL 13 - 18 Years: Male: 0.1 - 0.3 mg/dL Female: </= 0.3 mg/dL >/= 19 Years: </= 0.3 mg/dL
83	BCH BPH RHC RHR THL
84	CI	Bilirubin, Direct	0 - 14 Days: 0.3-0.7 mg/dL >/= 15 Days: 0.0-0.5 mg/dL
85	CI
86	BCH BPH CI RHC RHR THL	Bilirubin, Indirect	0 - 14 Days 0.1 - 9.9 mg/dL >/= 15 Days 0.0 - 1.2 mg/dL
87	BCH BPH CI RHC RHR THL
88	CI	Bilirubin, Indirect	0 - 14 Days: 0.1 - 9.9 mg/dL >/= 15 Days: 0.0 - 1.2 mg/dL
89	CI
90	BCH BPH CI RHC RHR THL	Bilirubin, Total	0 - 23 Hours < 6.0 mg/dL 1 - 14 Days 0.1 - 10.3 mg/dL >/= 15 Days 0.1 - 1.2 mg/dL
91	BCH BPH CI RHC RHR THL
92	RHC	Blood Culture ID by PCR	Not Detected
93	RHC
94	RHC	Bordetella pertussis DNA	Negative
95	RHC
96	RHC	Borrelia burgdorferi Ab Total (Lyme)	Negative
97	RHC
98	BCH BPH RHC RHR THL	Brain-Type Natriuretic Peptide (BNP)	0 Days - 11 Months < 24 pg/mL 1 Year - 5 Years < 30 pg/mL 6 Years - 10 Years < 15 pg/mL 11 Years - 14 Years < 21 pg/mL 15 Years - 20 Years < 20 pg/mL >/=21 Years < 100 pg/mL
99	BCH BPH RHC RHR THL
100	GMH RHC	NT-proBNP	< 300 pg/mL
101	GMH RHC
102	BCH BPH RHC RHR THL	Calcium	SERUM: 0 - 11 Months: 8.6 - 11.0 mg/dL 1 - 17 Years: 9.3 - 10.6 mg/dL 18 - 60 Years: 8.6 - 10.0 mg/dL 60 - 90 Years: 8.8 - 10.2 mg/dL >/= 91 Years: 8.2 - 9.6 mg/dL URINE: Random: Male: 0.9 - 37.9 mg/dL Female: 0.5 - 35.7 mg/dL Timed: CA Free Diet 5 - 40 mg/24hr Low to Average Intake 50 - 150 mg/24hr Average Intake 100 - 300 mg/24hr 0 - 11 Years: 2.0 - 4.0 mg/kg/24hr >/= 12 Years: 1.4 - 4.3 mg/kg/24hr
103	BCH BPH RHC RHR THL
104	CI	Calcium	0 - 11 Months: 8.5-11.0 mg/dL 1 - 17 Years: 9.0-10.5 mg/dL >/= 18 Years: 8.5-10.4 mg/dL
105	CI
106	RHC	Calcium/Creatinine Ratio, Urine	Male: < 0.24 mgca/mgcr Female: < 0.33 mgca/mgcr
107	RHC
108	BCH BPH GMH RHC RHR	Calcium, Ionized	WHOLE BLOOD: (Upstate) 0 - 29 Days: 1.00 - 1.50 mmol/L 1 - 6 Months: 0.95 - 1.50 mmol/L >/= 7 Months: 1.16 - 1.32 mmol/L PLASMA: (Midlands) All Ages: 1.09 - 1.30 mmol/L
109	BCH BPH GMH RHC RHR
110	GMH RHC	Calcium, Ionized Pre-Filter and Post Filter	WHOLE BLOOD: (Upstate) 1.16 - 1.32 mmol/L PLASMA: (Midlands) 1.09 - 1.30 mmol/L
111
112	CI	Cancer Antigen 125 (CA 125)	< 35.1 U/mL
113	CI
114	CI	Cancer Antigen 15-3 (CA 15-3)	< 23.6 U/mL
115	CI
116	CI	Cancer Antigen 19-9 (CA 19-9)	< 35.1 U/mL
117	CI
118	GMH	Carbamazepine (Tegretol)	4.0 - 12.0 ug/mL
119	RHC THL
120	RHC	Carbapenemase by PCR Screen/Isolate	Not Detected
121	RHC
122	CI	Carcinoembryonic Antigen (CEA)	< 3.1 ng/mL
123	CI
124	RHC	Cardiolipin Antibody IgA	< 14.0 APL U/mL Interpretive Data: < 14.0 Negative 14.0-20.0 Equivocal - Recommend to retest the patient after 4-6 weeks. > 20.0 Positive Antibody prevalence in autoimmune patients varies widely depending on disease area. The proportion of sera from a normal population found positive for the Cardiolipin IgA covered by the EliA Cardiolipin IgA test is below 5%, increasing with age, and men tend to show higher values. Expected values may vary depending on the population tested. A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated.
125	RHC
126	RHC	Cardiolipin Antibody IgG	< 10.0 GPL U/mL Interpretive Data: < 10.0 Negative 10.0-40.0 Weak Positive - Recommend to retest the patient after 8-12 weeks. > 40.0 Positive The expected value in the normal population is negative. However, low percentages (up to 5%) of apparently healthy, asymptomatic individuals have been reported to be positive for ACA. Cardiolipin antibodies show the following prevalences in APS: Primary APS: ACA IgG 81%, ACA IgM 40%, ACA IgA 24% Secondary APS: ACA IgG 85%, ACA IgM 65%, ACA IgA 10%. A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated.
127	RHC
128	RHC	Cardiolipin Antibody IgM	< 10.0 MPL U/mL Interpretive Data: < 10.0 Negative 10.0-40.0 Weak Positive - Recommend to retest the patient after 8-12 weeks. > 40.0 Positive The expected value in the normal population is negative. However, low percentages (up to 5%) of apparently healthy, asymptomatic individuals have been reported to be positive for ACA. Cardiolipin antibodies show the following prevalences in APS: Primary APS: ACA IgG 81%, ACA IgM 40%, ACA IgA 24% Secondary APS: ACA IgG 85%, ACA IgM 65%, ACA IgA 10% A definitive clinical diagnosis should not be based on the results of a single diagnostic method, but should only be made by the physician after all clinical and laboratory findings have been evaluated.
129	RHC
130	RHC	CD4 Level/ T&B Cell Enumeration Panel (CD3, CD4, CD8, CD19, CD16/56) / T Helper/Suppressor, Whole Blood(CD3, CD4, CD8)	Midlands:
131	RHC	CD3 (T Cells), Whole Blood	0 - 2 Months: 53.0 - 84.0 % 3 - 5 Months: 51.0 - 77.0 % 6 - 11 Months: 49.0 - 76.0 % 12 - 23 Months: 53.0 - 75.0 % 2 - 5 Years: 56.0 - 75.0 % 6 - 11 Years: 60.0 - 76.0 % 12 - 17 Years: 56.0 - 84.0 % >/= 18 Years: 58.0 - 84.0 %
132	RHC	CD3 Absolute Count, Whole Blood	0 - 2 Months 2500 - 5500 Cells/uL 3 - 5 Months 2500 - 5600 Cells/uL 6 - 11 Months 1900 - 5900 Cells/uL 12 - 23 Months 2100 - 6200 Cells/uL 2 - 5 Years 1400 - 3700 Cells/uL 6 - 11 Years 1200 - 2600 Cells/uL 12 - 17 Years 1000 - 2200 Cells/uL >/= 18 Years 856 - 2237 Cells/uL
133	RHC	CD4 (Helper T Cells), Whole Blood	0 - 2 Months 35.0 - 64.0 % 3 - 5 Months 35.0 - 56.0 % 6 - 11 Months 31.0 - 56.0 % 12 - 23 Months 32.0 - 51.0 % 2 - 5 Years 28.0 - 47.0 % 6 - 11 Years 31.0 - 47.0 % 12 - 17 Years 31.0 - 52.0 % >/= 18 Years 33.6 - 64.8 %
134	RHC	CD4 Absolute Count, Whole Blood	0 - 2 Months 1600 - 4000 Cells/uL 3 - 5 Months 1800 - 4000 Cells/uL 6 - 11 Months 1400 - 4300 Cells/uL 12 - 23 Months 1300 - 3400 Cells/uL 2 - 5 Years 700 - 2200 Cells/uL 6 - 11 Years 650 - 1500 Cells/uL 12 - 17 Years 530 - 1300 Cells/uL >/= 18 Years 518 - 1472 Cells/uL
135	RHC	CD8 (Suppressor T Cells), Whole Blood	0 - 2 Months 12.0 - 28.0 % 3 - 5 Months 12.0 - 23.0 % 6 - 11 Months 12.0 - 24.0 % 12 - 23 Months 14.0 - 30.0 % 2 - 5 Years 16.0 - 30.0 % 6 - 17 Years 18.0 - 35.0 % >/= 18 Years 13.0 - 37.6 %
136	RHC	CD8 Absolute Count, Whole Blood	0 - 2 Months 560 - 1700 Cells/uL 3 - 5 Months 590 - 1600 Cells/uL 6 - 11 Months 500 - 1700 Cells/uL 12 - 23 Months 620 - 2000 Cells/uL 2 - 5 Years 490 - 1300 Cells/uL 6 - 11 Years 370 - 1100 Cells/uL 12 - 17 Years 330 - 920 Cells/uL >/= 18 Years 205 - 924 Cells/uL
137	RHC	CD16/56 NK Cells, Whole Blood	0 - 2 Months 4.0 - 18.0 % 3 - 5 Months 3.0 - 14.0 % 6 - 11 Months 3.0 - 15.0 % 2 - 11 Years 4.0 - 17.0 % 12 - 17 Years 3.0 - 22.0 % >/= 18 Years 4.3 - 26.6 %
138	RHC	CD16/56 Absolute Count, Whole Blood	0 - 2 Months 170 - 1100 Cells/uL 3 - 5 Months 170 - 830 Cells/uL 6 - 11 Months 160 - 950 Cells/uL 12 - 23 Months 180 - 920 Cells/uL 2 - 5 Years 130 - 720 Cells/uL 6 - 11 Years 100 - 480 Cells/uL 12 - 17 Years 70 - 480 Cells/uL >/= 18 Years 74 - 562 Cells/uL
139	RHC	CD19 % (B cells), Whole Blood	0 - 2 Months 6.0 - 32.0 % 3 - 5 Months 11.0 - 41.0 % 6 - 11 Months 14.0 - 37.0 % 12 - 23 Months 16.0 - 35.0 % 2 - 5 Years 14.0 - 33.0 % 6 - 11 Years 13.0 - 27.0 % 12 - 17 Years 6.0 - 23.0 % >/= 18 Years 5.7 - 24.9 %
140	RHC	CD19 Absolute Count, Whole Blood	0 - 2 Months 300 - 2000 Cells/uL 3 - 5 Months 430 - 3000 Cells/uL 6 - 11 Months 610 - 2600 Cells/uL 12 - 23 Months 720 - 2600 Cells/uL 2 - 5 Years 390 - 1400 Cells/uL 6 - 11 Years 270 - 860 Cells/uL 12 - 17 Years 110 - 570 Cells/uL >/= 18 Years 87 - 507 Cells/uL
141	RHC
142	BCH BPH RHC RHR THL	Cell Count, Fluid	CSF: Nucleated Cells: 0 - 1 Year: 0-22 Cells/uL 1 - 12 Years: 0 - 7 Cells/uL > 12 Years: 0 - 5 Cells/uL RBCs: 0 - 2 Cells/uL BODY FLUID: Nucleated Cells: Synovial Fluids: 0-150 mm3 All Other Fluids: 0-500 mm3
143	BCH BPH RHC RHR THL
144	RHC	Chlamydia trachomatis, NAAT	Negative
145	RHC
146	BCH BPH RHC RHR THL	Chloride	SERUM: 0 - 29 Days: 98 - 113 mmol/L >/= 30 Days: 98 - 107 mmol/L URINE: Random: No Reference Ranges Established Timed: Varies significantly with hydration and chloride intake. 0 - 27 Days: No Reference Ranges Established 28 Days - 23 Months: 2 - 10 mmol/24 hrs 2 - 17 Years: 15 - 40 mmol/24 hrs >/= 18 Years: 110 - 250 mmol/24 hrs
147	BCH BPH RHC RHR THL
148	CI	Chloride	0 - 29 Days: 98-113 mmol/L >/= 30 Days: 98-107 mmol/L
149	CI
150	RHC	Chloride, Sweat	0 - 29 mmol/L Interpretive Data: </= 29 mmol/L - CF unlikely 30-59 mmol/L - Intermediate range, needs further study to establish or rule out a CF diagnosis. >/= 60 mmol/L - Indicative of CF for individuals presenting with a positive screen, clinical features consistent with CF, or a positive family history.
151	RHC
152	BCH BPH RHC RHR THL	CKMB	Male: < 7.7 ng/mL Female: < 4.3 ng/mL
153	BCH BPH RHC RHR THL
154	BCH BPH RHC	Clostridium Difficile Toxin B gene by PCR	Negative
155	BCH BPH RHC
156	BCH BPH RHC RHR THL	CO2	0 - 27 Days: 14 - 27 mmol/L 28 Days - 11 Months: 20 - 28 mmol/L >/= 1 Year: 22 - 29 mmol/L
157	BCH BPH RHC RHR THL
158	CI		0 - 27 Days: 15-22 mmol/L 28 Days - 11 Months: 20-28 mmol/L >/= 1 Year: 20-30 mmol/L
159	CI
160	RHC	Complement, C-3	0 - 14 Days: 57 - 129 mg/dL 15 Days - 11 Months: 58 - 169 mg/dL 1 - 18 Years: 90 - 161 mg/dL >/= 19 years: 90 - 180 mg/dL
161	RHC
162	RHC	Complement, C-4	0 Days - 11 Months: 7 - 31 mg/dL 1 - 18 Years: 13 - 38 mg/dL >/= 19 Years: 10 - 40 mg/dL
163	RHC
164	BCH BPH CI RHC RHR THL	Complete Blood Count (CBC):	.
165	BCH BPH CI RHC RHR THL	WBC	Male: 0 - 14 Days 8.0 - 15.4 K/uL 15 - 30 Days 7.8 - 15.9 K/uL 31 - 60 Days 8.1 - 15.0 K/uL 2 - 5 Months 6.5 - 13.3 K/uL 6 - 23 Months 6.0 - 13.4 K/uL 2 - 5 Years 5.1 - 13.4 K/uL 6 - 11 Years 4.3 - 11.0 K/uL 12 - 17 Years 3.8 - 9.8 K/uL >/= 18 Years 3.5 - 10.8 K/uL Female: 0 - 14 Days 8.2 - 14.6 K/uL 15 - 30 Days 8.4 - 14.4 K/uL 31 - 60 Days 7.1 - 14.7 K/uL 2 - 5 Months 6.0 - 13.3 K/uL 6 - 23 Months 6.5 - 13.0 K/uL 2 - 5 Years 4.9 - 13.2 K/uL 6 - 11 Years 4.3 - 11.4 K/uL 12 - 17 Years 4.2 - 9.4 K/uL >/=18 Years 3.5 - 10.8 K/uL
166	BCH BPH CI RHC RHR THL	RBC	Male: 0 - 14 Days: 4.10 - 5.55 M/uL 15 - 30 Days: 3.16 - 4.63 M/uL 31 - 60 Days: 3.02 - 4.22 M/uL 2 - 5 Months: 3.43 - 4.80 M/uL 6 - 23 Months: 4.03 - 5.07 M/uL 2 - 5 Years: 3.89 - 4.97 M/uL 6 - 11 Years: 3.96 - 5.03 M/uL 12 - 17 Years: 4.03 - 5.29 M/uL >/= 18 Years: 4.17 - 5.89 M/uL Female: 0 - 14 Days: 4.12 - 5.74 M/uL 15 - 30 Days: 3.32 - 4.80 M/uL 31 - 60 Days: 2.93 - 3.87 M/uL 2 - 5 Months: 3.45 - 4.75 M/uL 6 - 23 Months: 3.97 - 5.01 M/uL 2 - 5 Years: 3.84 - 4.92 M/uL 6 - 11 Years: 3.90 - 4.96 M/uL 12 - 17 Years: 3.93 - 4.90 M/uL >/= 18 Years: 3.86 - 5.35 M/uL
167	BCH BPH CI RHC RHR THL	HGB	Male: 0 - 14 Days: 13.9 - 19.1 g/dL 15 - 30 Days: 10.0 - 15.3 g/dL 31 - 60 Days: 8.9 - 12.7 g/dL 2 - 5 Months: 9.6 - 12.4 g/dL 6 - 23 Months: 10.1 - 12.5 g/dL 2 - 5 Years: 10.2 - 12.7 g/dL 6 - 11 Years: 10.7 - 13.4 g/dL 12 - 17 Years: 11.0 - 14.5 g/dL >/= 18 Years: 12.7 - 17.2 g/dL Female: 0 - 14 Days: 13.4 - 20.0 g/dL 15 - 30 Days: 10.8 - 14.6 g/dL 31 - 60 Days: 9.2 - 11.4 g/dL 2 - 5 Months: 9.9 - 12.4 g/dL 6 Months - 5 Years: 10.2 - 12.7 g/dL 6 - 11 Years: 10.6 - 13.2 g/dL 12 - 17 Years: 10.8 - 13.3 g/dL >/= 18 Years: 11.0 - 15.4 g/dL
168	BCH BPH CI RHC RHR THL	HCT	Male: 0 - 14 Days: 39.8 - 53.6 % 15 - 30 Days: 30.5 - 45.0 % 31 - 60 Days: 26.8 - 37.5 % 2 - 5 Months: 28.6 - 37.2 % 6 - 23 Months:30.8 - 37.8 % 2 - 5 Years: 31.0 - 37.7 % 6 - 11 Years: 32.2 - 39.8 % 12 - 17 Years: 33.9 - 43.5 % >/= 18 Years: 39.4 - 51.6 % Female: 0 - 14 Days: 39.6 - 57.2 % 15 - 30 Days: 32.0 - 44.5 % 31 - 60 Days: 27.7 - 35.1 % 2 - 5 Months: 29.5 - 37.1 % 6 - 23 Months:30.9 - 37.9 % 2 - 5 Years: 31.2 - 37.8 % 6 - 11 Years: 32.4 - 39.5 % 12 - 17 Years: 33.4 - 40.4 % >/= 18 Years: 35.6 - 47.3 %
169	BCH BPH CI RHC RHR THL	MCV	Male: 0 - 14 Days: 91.3 - 103.1 fL 15 - 30 Days: 89.4 - 99.7 fL 31 - 60 Days: 84.3 - 94.2 fL 2 - 5 Months: 74.1 - 87.5 fL 6 - 23 Months:69.5 - 81.7 fL 2 - 5 Years: 71.3 - 84.0 fL 6 - 11 Years: 74.4 - 86.1 fL 12 - 17 Years: 76.7 - 89.2 fL >/= 18 Years: 79.0 - 100.0 fL Female: 0 - 14 Days: 92.7 - 106.4 fL 15 - 30 Days: 90.1 - 103.0 fL 31 - 60 Days: 83.4 - 96.4 fL 2 - 5 Months: 74.8 - 88.3 fL 6 - 23 Months:71.3 - 82.6 fL 2 - 5 Years: 72.3 - 85.0 fL 6 - 11 Years: 75.9 - 87.6 fL 12 - 17 Years: 76.9 - 90.6 fL >/= 18 Years: 79.0 - 100.0 fL
170	BCH BPH CI RHC RHR THL	MCH	Male: 0 - 14 Days: 31.3 - 35.6 pg 15 - 30 Days: 29.9 - 34.1 pg 31 - 60 Days: 27.8 - 32.0 pg 2 - 5 Months: 24.4 - 28.9 pg 6 - 23 Months:22.7 - 27.2 pg 2 - 5 Years: 23.7 - 28.3 pg 6 - 11 Years: 24.9 - 29.2 pg 12 - 17 Years: 25.2 - 30.2 pg >/= 18 Years: 25.7 - 33.2 pg Female: 0 - 14 Days: 31.1 - 35.9 pg 15 - 30 Days: 30.4 - 35.3 pg 31 - 60 Days: 28.0 - 32.5 pg 2 - 5 Months: 24.4 - 29.5 pg 6 - 23 Months:23.2 - 27.5 pg 2 - 5 Years: 23.7 - 28.6 pg 6 - 11 Years: 24.8 - 29.5 pg 12 - 17 Years: 24.8 - 30.2 pg >/= 18 Years: 23.7 - 32.9 pg
171	BCH BPH CI RHC RHR THL	MCHC	Male: 0 - 14 Days: 33.0 - 35.7 g/dL 15 - 30 Days: 32.7 - 35.1 g/dL 31 - 60 Days: 32.3 - 34.8 g/dL 2 - 5 Months: 31.9 - 34.4 g/dL 6 - 23 Months:31.6 - 34.4 g/dL 2 - 5 Years: 32.0 - 34.7 g/dL 6 - 11 Years: 32.2 - 34.9 g/dL 12 - 17 Years: 31.8 - 34.8 g/dL >/= 18 Years: 30.0 - 36.5 g/dL Female: 0 - 14 Days: 33.4 - 35.4 g/dL 15 - 30 Days: 33.2 - 35.0 g/dL 31 -60 Days: 32.5 - 34.9 g/dL 2 - 5 Months: 32.1 - 34.4 g/dL 6 - 23 Months:31.9 - 34.2 g/dL 2 - 11 Years: 31.8 - 34.6 g/dL 12 - 17 Years: 31.5 - 34.2 g/dL >/= 18 Years: 30.0 - 36.5 g/dL
172	BCH BPH CI RHC RHR THL	RDW-CV	Male: 0 - 14 Days: 14.8 - 17.0 % 15 - 30 Days: 14.3 - 16.8 % 31 - 60 Days: 13.8 - 16.1 % 2 - 5 Months: 12.4 - 15.3 % 6 - 23 Months:12.9 - 15.6 % 2 - 5 Years: 12.5 - 14.9 % 6 - 11 Years: 12.3 - 14.1 % 12 - 17 Years: 12.4 - 14.5 % >/= 18 Years: 11.6 - 16.0 % Female: 0 - 14 Days: 14.6 - 17.3 % 15 - 30 Days: 14.4 - 16.2 % 31 - 60 Days: 13.6 - 15.8 % 2 - 5 Months: 12.2 - 14.3 % 6 - 23 Months:12.7 - 15.1 % 2 - 5 Years: 12.4 - 14.9 % 6 - 11 Years: 12.2 - 14.4 % 12 - 17 Years: 12.3 - 14.6 % >/= 18 Years: 11.6 - 16.0 %
173	BCH BPH CI RHC RHR THL	RDW-SD	Male: 0 - 14 Days: 51.0 - 61.7 fL 15 - 30 Days: 46.3 - 57.3 fL 31 - 60 Days: 43.9 - 52.8 fL 2 - 5 Months: 35.3 - 45.7 fL 6 - 23 Months:35.3 - 45.7 fL 2 - 5 Years: 35.3 - 42.8 fL 6 - 11 Years: 35.1 - 41.7 fL 12 - 17 Years: 36.7 - 43.8 fL >/= 18 Years: 35.1 - 43.9 fL Female: 0 - 14 Days: 51.4 - 65.7 fL 15 - 30 Days: 47.2 - 59.8 fL 31 - 60 Days: 43.0 - 55.0 fL 2 - 5 Months: 35.2 - 45.1 fL 6 - 23 Months:34.9 - 42.4 fL 2 - 5 Years: 34.9 - 42.0 fL 6 - 11 Years: 35.5 - 41.8 fL 12 - 17 Years: 37.1 - 44.2 fL >/= 18 Years: 36.4 - 46.3 fL
174	BCH BPH CI RHC RHR THL	MPV	Beckman: 6.9 - 10.6 fL Sysmex: Male: 0 - 14 Days: 10.2 - 11.9 fL 15 - 30 Days: 10.1 - 12.1 fL 31 - 60 Days: 9.2 - 10.8 fL 2 - 5 Months: 8.9 - 10.6 fL 6 - 23 Months:8.7 - 10.5 fL 2 - 5 Years: 9.0 - 10.9 fL 6 - 11 Years: 9.2 - 11.4 fL 12 - 17 Years: 9.6 - 11.8 fL >/= 18 Years: Sysmex: 9.2 - 12.8 fL Beckman: 6.9 - 10.6 fL Female: 0 - 14 Days: 10.4 - 12.0 fL 15 - 30 Days: 10.0 - 12.2 fL 31 - 60 Days: 9.4 - 11.1 fL 2 - 5 Months: 9.0 - 10.9 fL 6 - 23 Months: 8.8 - 10.6 fL 2 - 5 Years: 8.9 - 11.0 fL 6 - 11 Years: 9.3 - 11.3 fL 12 - 17 Years: 9.6 - 11.7 fL >/= 18 Years: 9.2 - 12.8 fL
175	BCH BPH CI RHC RHR THL	Platelet Count	Male: 0 - 14 Days: 218 - 419 K/uL 15 - 30 Days: 248 - 586 K/uL 31 - 60 Days: 229 - 562 K/uL 2 - 5 Months: 244 - 529 K/uL 6 - 23 Months:206 - 445 K/uL 2 - 5 Years: 202 - 403 K/uL 6 - 11 Years: 206 - 369 K/uL 12 - 17 Years: 175 - 332 K/uL >/= 18 Years: 150 - 400 K/uL Female: 0 - 14 Days: 144 - 449 K/uL 15 - 30 Days: 279 - 571 K/uL 31 - 60 Days: 331 - 597 K/uL 2 - 5 Months: 247 - 580 K/uL 6 - 23 Months:214 - 459 K/uL 2 - 5 Years: 189 - 394 K/uL 6 - 11 Years: 199 - 367 K/uL 12 - 17 Years: 194 - 345 K/uL >/= 18 Years: 150 - 400 K/uL
176	BCH BPH CI RHC RHR THL	Nucleated RBCs	ABSOLUTE: 0 - 3 Days: 0.1 - 8.3 >/= 4 Days: 0.0 - 0.2 PERCENT: 0 - 3 Days: 0 - 8 % >/= 4 Days: 0 %
177	BCH BPH CI RHC RHR THL	Differential White Count	.
178	BCH BPH CI RHC RHR THL	Neutrophils, Absolute	Male: 0 - 14 Days: 1.60 - 6.06 K/uL 15 - 30 Days: 1.18 - 5.45 K/uL 31 - 60 Days: 0.83 - 4.23 K/uL 61 - 180 Days:0.97 - 5.45 K/uL 6 - 23 Months:1.19 - 7.21 K/uL 2 - 5 Years: 1.54 - 7.92 K/uL 6 - 11 Years: 1.63 - 7.55 K/uL 12 - 17 Years: 1.54 - 7.04 K/uL >/= 18 Years: 1.78 - 5.38 K/uL Female: 0 - 14 Days: 1.73 - 6.75 K/uL 15 - 30 Days: 1.23 - 4.80 K/uL 31 - 60 Days: 1.00 - 4.68 K/uL 61 - 180 Days:1.04 - 7.20 K/uL 6 - 23 Months:1.27 - 7.18 K/uL 2 - 5 Years: 1.60 - 8.29 K/uL 6 - 11 Years: 1.64 - 7.87 K/uL 12 - 17 Years: 1.82 - 7.47 K/uL >/= 18 Years: 1.56 - 6.13 K/uL
179	BCH BPH CI RHC RHR THL	Lymphocytes, Absolute	Male 0 - 14 Days: 2.07 - 7.53 K/uL 15 - 30 Days: 2.11 - 8.38 K/uL 31 - 60 Days: 2.47 - 7.95 K/uL 61 - 180 Days: 2.45 - 8.89 K/uL 6 - 23 Months: 1.56 - 7.83 K/uL 2 - 5 Years: 1.13 - 5.52 K/uL 6 - 11 Years: 0.97 - 3.96 K/uL 12 - 17 Years 0.97 - 3.26 K/uL >/= 18 Years: 1.32 - 3.57 K/uL Female 0 - 14 Days: 1.75 - 8.00 K/uL 15 - 30 Days: 2.42 - 8.20 K/uL 31 - 60 Days: 2.29 - 9.14 K/uL 61 - 180 Days: 2.14 - 8.99 K/uL 6 - 23 Months: 1.52 - 8.99 K/uL 2 - 5 Years: 1.25 - 5.77 K/uL 6 - 11 Years: 1.16 - 4.28 K/uL 12 - 17 Years: 1.16 - 3.33 K/uL >/= 18 Years: 1.18 - 3.74 K/uL
180	BCH BPH CI RHC RHR THL	Monocytes, Absolute	Male: 0 - 14 Days: 0.52 - 1.77 K/uL 15 - 30 Days: 0.28 - 1.38 K/uL 31 - 60 Days: 0.28 - 1.05 K/uL 2 - 5 Months: 0.28 - 1.07 K/uL 6 - 23 Months: 0.25 - 1.15 K/uL 24 - 35 Months: 0.19 - 0.94 K/uL 3 - 5 Years: 0.30 - 0.90 K/uL 6 - 16 Years: 0.20 - 0.80 K/uL >/= 17 Years: 0.30 - 0.82 K/uL Female: 0 - 14 Days: 0.57 - 1.72 K/uL 15 - 30 Days: 0.42 - 1.21 K/uL 31 - 60 Days: 0.28 - 1.21 K/uL 2 - 5 Months: 0.24 - 1.17 K/uL 6 - 23 Months: 0.26 - 1.08 K/uL 24 - 35 Months: 0.24 - 0.92 K/uL 3 - 5 Years: 0.30 - 0.90 K/uL 6 - 16 Years: 0.20 - 0.80 K/uL >/= 17 Years: 0.24 - 0.86 K/uL
181	BCH BPH CI RHC RHR THL	Eosinophils, Absolute	Male: 0 - 14 Days: 0.12 - 0.66 K/uL 15 - 30 Days: 0.08 - 0.80 K/uL 31 - 60 Days: 0.05 - 0.57 K/uL 2 - 5 Months: 0.03 - 0.61 K/uL 6 - 23 Months: 0.02 - 0.82 K/uL 24 - 35 Months: 0.03 - 0.53 K/uL 3 - 11 Years: 0.00 - 0.50 K/uL 12 - 16 Years: 0.10 - 0.20 K/uL >/= 17 Years: 0.04 - 0.54 K/uL Female: 0 - 14 Days: 0.09 - 0.64 K/uL 15 - 30 Days: 0.06 - 0.75 K/uL 31 - 60 Days: 0.04 - 0.63 K/uL 2 - 5 Months: 0.02 - 0.74 K/uL 6 - 23 Months: 0.02 - 0.58 K/uL 24 - 35 Months: 0.03 - 0.46 K/uL 3 - 11 Years: 0.00 - 0.50 K/uL 12- 16 Years: 0.10 - 0.20 K/uL >/= 17 Years 0.04 - 0.36 K/uL
182	BCH BPH CI RHC RHR THL	Basophils, Absolute	Male: 0 - 14 Days: 0.02 - 0.11 K/uL 15 - 30 Days: 0.01 - 0.07 K/uL 2 - 35 Months: 0.01 - 0.06 K/uL 3 - 16 Years: 0.00 - 0.10 K/uL >/= 17 Years: 0.01 - 0.08 K/uL Female: 0 - 14 Days 0.02 - 0.07 K/uL 15 - 30 Days: 0.01 - 0.06 K/uL 31 - 60 Days: 0.01 - 0.05 K/uL 2 - 5 Months: 0.01 - 0.07 K/uL 6 - 35 Months: 0.01 - 0.06 K/uL 3 - 16 Years: 0.00 - 0.10 K/uL >/= 17 Years: 0.01 - 0.08 K/uL
183	BCH BPH CI RHC RHR THL	Immature Granulocytes, Absolute	0.00 - 0.03 K/uL
184	BCH BPH CI RHC RHR THL	Unidentified Cells, %	0%
185	BCH BPH CI RHC RHR THL
186	RHC	Cortisol	0 - 30 Days: 0.5 - 14.0 ug/dL 1 - 11 Months: 0.7 - 20.0 ug/dL 1 - 11 Years: 2.4 - 15.0 ug/dL 12 - 18 Years: 3.6 - 17.0 ug/dL >/= 19 Years: Morning hours (6 - 10 am): 4.8 - 19.5 ug/dL Afternoon hours (4 - 8 pm): 2.5 - 11.9 ug/dL
187	RHC
188	RHC	Cortisol Stimulation	> 20 ug/dL
189	RHC
190	RHC	Cotinine	Negative
191	RHC
192	RHC	COVID-19 PCR	Negative
193	RHC
194	RHC	COVID-19 IgG	Negative
195	RHC
196	RHC	C-peptide	0.78 - 5.19 ng/mL
197	RHC
198	BCH BPH RHC RHR THL	C-Reactive Protein (CRP)	INFLAMMATION: 0 - 12 Months </=15.2 mg/L 1 - 6 Years: </=25.3 mg/L 6 - 11 Years: </=11.8 mg/L 11 - 15 Years: </=18.1 mg/L 15 - 21 Years: </=24.2 mg/L >/= 21 Years: </=5.0 mg/L
199	BCH BPH RHC RHR THL
200	BCH BPH RHC RHR THL	Creatinine	SERUM: 0 - 3 Days: 0.30 - 1.00 mg/dL 4 Days - 11 Months: 0.20 - 0.40 mg/dL 1 - 11 Years: 0.30 - 0.70 mg/dL 12 - 14 Years: 0.50 - 1.00 mg/dL 15 - 17 Years: Male: 0.65 - 1.10 mg/dL Female: 0.59 - 0.88 mg/dL >/= 18 Years: Male: 0.67 - 1.17 mg/dL Female: 0.51 - 0.95 mg/dL URINE: Random: No Established Reference Range Timed/24 Hr: Male: 980 - 2200 mg/24 hours Female: 720 - 1510 mg/24 hours Timed Concentration: Male: 40.00 - 278.00 mg/dL Female: 29.00 - 226.00 mg/dL Clearance: 66 - 143 mL/min/1.73 m2 24 hr Excretion (Output): 0 - 23 Months: 9.0 - 18.0 mg/kg/24 hr 2 - 12 Years: 18.0 - 24.0 mg/kg/24 hr 13 - 17 Years: Male: 27.0 - 30.0 mg/kg/24 hr Female: 18.0 - 24.0 mg/kg/24hr >/=18 Years: Male:12.1 - 28.9 mg/kg/24hr Female:10.7 - 26.0 mg/kg/24hr BODY FLUID: Pleural and Peritoneal: Urine extravasation will usually present as a transudate with a high concentration of creatinine and urea and a low concentration of glucose and pH. Peritoneal Fluid creatinine concentration will be markedly elevated (2.0-10.0 mg/dL), with the creatinine to serum creatinine greater than 1.0. In the situation in which fluid aspiration inadvertently consists of urine from the bladder, the urea to creatinine ratio should be much higher than for peritoneal fluid from which urea is more readily absorbed than creatinine. Leakage of urine should be suspected when the fluid has a high creatinine concentration relative to that in serum from a simultaneously collected blood specimen.
201	BCH BPH RHC RHR THL
202	CI	Creatinine	0 - 14 Days: 0.42 - 1.05 mg/dL 15 Days - 11 Months: 0.31 - 0.53 mg/dL 1 - 11 Years: 0.39 - 0.69 mg/dL 12 - 14 Years: 0.57 - 0.80 mg/dL 15 - 17 Years: Female: 0.59 - 0.88 mg/dL Male: 0.65 - 1.10 mg/dL >/= 18 Years: Female: 0.57 - 1.11 mg/dL Male: 0.72 - 1.25 mg/dL
203	CI
204	BCH BPH RHC RHR THL	Creatine Phosphokinase (CPK/CK)	Male: 20 - 200 IU/L Female: 20 - 180 IU/L
205	BCH BPH RHC RHR THL
206	BCH BPH RHC	Cryptococcal Antigen, Blood/CSF	Negative
207	BCH BPH RHC
208	RHC	Cryptosporidium Antigen	Negative
209	RHC
210	RHC	Cryptosporidium Stain	Absent
211	RHC
212	BCH BPH RHC THL	Crystals, Body Fluid	No crystals identified
213	BCH BPH RHC THL
214	RHC	Cyclic Citrullinated Peptide (CCP) AB EliA	0.4 - 6.9 U/mL Interpretive Data: 0.4-6.9: Negative 7.0-10.0: Equivocal > 10.0: Positive
215	RHC
216	RHC	Cyclosporine	100 - 400 ng/mL
217	RHC
218	RHC	Cytomegalovirus (CMV) IgG	Negative
219	RHC
220	RHC	Cytomegalovirus (CMV) IgM	Negative
221	RHC
222	BCH BPH RHC RHR THL	D-Dimer FEU	< 0.50 ug/mL Interpretive Data: For Outpatients with a value of less than 0.50 ug/ml FEU and with low to moderate clinical pretest probability, this method is FDA cleared to exclude pulmonary emoblism (PE) and as an aid in the diagnosis of deep venous thrombosis (DVT).
223	BCH BPH RHC RHR THL
224	RHC	DHEA Sulfate	Male: 11 Years - 14 Years: 26.0 - 380.0 ug/dL 15 Years - 20 Years: 86.0 - 634.0 ug/dL 21 Years - 24 Years: 238.4 - 539.3 ug/dL 25 Years - 34 Years: 167.9 - 591.9 ug/dL 35 Years - 44 Years: 139.7 - 484.4 ug/dL 45 Years - 54 Years: 136.2 - 447.6 ug/dL 55 Years - 64 Years: 48.6 - 361.8 ug/dL 65 Years - 69 Years: 228.5 - 283.6 ug/dL >/= 70 Years 34.5 - 568.9 ug/dL Female: 11 Years - 14 Years: 26.0 - 380.0 ug/dL 15 Years - 20 Years: 50.0 - 459.0 ug/dL 21 Years - 24 Years: 134.2 - 407.4 ug/dL 25 Years - 34 Years: 95.8 - 511.7 ug/dL 35 Years - 44 Years: 74.8 - 410.2 ug/dL 45 Years - 54 Years: 56.2 - 282.9 ug/dL 55 Years - 64 Years: 29.7 - 182.2 ug/dL 65 Years - 69 Years: 33.6 - 78.9 ug/dL >/= 70 Years 25.9 - 460.2 ug/dL
225	RHC
226	BCH BPH RHC RHR THL	Digoxin	0.8 - 2.0 ng/mL
227	BCH BPH RHC RHR THL
228	BPH RHC THL	Dilantin Total (Phenytoin)	Total: 10.0 - 20.0 ug/mL Free: 1.0 - 2.0 ug/mL Free %: 10 - 20%
229	BPH RHC THL
230	RHC	Dilute Russell Viper Venom (dRVVT)	No evidence of phospholipid inhibitor
231	RHC
232	BCH BPH RHC RHR THL	Drug Screen, Urine	.
233	BCH BPH RHC RHR THL	Alcohol	Negative (cutoff 40 ng/mL)
234	BCH BPH RHC RHR THL	Amphetamines	Negative (cutoff 500 ng/mL)
235	BCH BPH RHC RHR THL	Barbiturates	Negative (cutoff 200 ng/mL)
236	BCH BPH RHC RHR THL	Benzodiazepines	Negative (cutoff 200 ng/mL)
237	GMH RHC	Buprenorphine	Negative (cutoff 5 ng/mL)
238	BCH BPH RHC RHR THL	Cannabinoids	Negative (cutoff 50 ng/mL)
239	BCH BPH RHC RHR THL	Cocaine Metabolites	Negative (cutoff 150 ng/mL)
240	BCH BPH RHC RHR THL	Codeine	Negative (cutoff 2000 ng/mL)
241	BCH BPH RHC RHR THL	Ecstasy (MDMA)	Negative (cutoff 500 ng/mL)
242	BCH BPH RHC RHR THL	Metamphetamine	Negative (cutoff 500 ng/mL)
243	BCH BPH RHC RHR THL	Methadone	Negative (cutoff 300 ng/mL)
244	GMH	Morphine	Negative (cutoff 2000 ng/mL)
245	BCH BPH RHC RHR THL	Opiates	Negative (cutoff 300 ng/mL)
246	BCH BPH RHC RHR THL	Oxycodone	Negative (cutoff 100 ng/mL)
247	RHC	Phencyclidine	Negative (cutoff 25 ng/mL)
248	GMH	Tramadol	Negative (cutoff 200 ng/mL)
249	GMH	Tricyclics	Negative (cutoff 300 ng/mL)
250	BCH BPH RHC RHR	Fentanyl	Negative (cutoff 1 ng/mL)
251	BCH BPH RHC RHR
252	RHC	Epstein Barr Virus (EBV) VCA IgG	Negative
253	RHC
254	RHC	Epstein Barr Virus (EBV) VCA IgM	Negative
255	RHC
256	BCH BPH RHC THL	Erythrocyte Sedimentation Rate (ESR)	ESR PLUS: Male: 0 - 49 Years: 0-15 mm/hr 50 - 84 Years: 0-20 mm/hr >/= 85 Years: 0-30 mm/hr Female: 0 - 49 Years: 0-20 mm/hr 50 - 84 Years: 0-30 mm/hr >/= 85 Years: 0-42 mm/hr ISED: Male: 0 - 11 Months: 0 - 2 mm/hr 1 - 11 Years: 3 - 13 mm/hr 12 - 49 Years: 0 - 15 mm/hr >/= 50 Years: 0 - 20 mm/hr Female: 0 - 11 Months: 0 - 2 mm/hr 1 - 11 Years: 3 - 13 mm/hr 12 - 49 Years: 0 - 20 mm/hr >/= 50 Years: 0 - 30 mm/hr
257	BCH BPH RHC THL
258	RHC	Estradiol	Male: 11 - 43 pg/mL Female >/= 20 Years: Follicular: 31 - 90 pg/mL Ovulation: 60 - 533 pg/mL Luteal: 60 - 232 pg/mL Postmenopausal: < 5 - 138 pg/mL 1st trimester: 154 - 3243 pg/mL 2nd Trimester: 1561 - 21280 pg/mL 3rd Trimester: 8525 - >30000 pg/mL
259	RHC
260	RHC	Coagulation Factors	.
261	RHC	Factor II	70-120 %
262	RHC	Factor V	70-120 %
263	RHC	Factor VII	55-170 %
264	RHC	Factor VIII	60-150 %
265	RHC	Factor IX	60-150 %
266	RHC	Factor X	70-120 %
267	RHC	Factor XI	60-150 %
268	RHC	Factor VIII Related Antigen (vWF Antigen)	> 49 %
269	RHC
270	RHC	Fecal Fat, Qualitative	Negative* *Small amount of neutral fat is normal.
271	RHC
272	RHC	Fecal Lactoferrin	Negative
273	RHC
274	RHC	Fecal Occult Blood, Immunochemical	Negative
275	RHC
276	RHC	Ferritin	0 - 30 Days: 150.0 - 973.0 ng/mL 1 - 5 Months: 8.5 - 580.0 ng/mL 6 Months - 14 Years: 14.0 - 101.0 ng/mL 15 - 19 Years: Male: 20.9 - 173.0 ng/mL Female: 3.9 - 114.0 ng/mL >/=20 Years: Male: 30.0 - 400.0 ng/mL Female: 13.0 - 150.0 ng/mL
277	RHC
278	CI	Ferritin	Female: 0 - 3 Days: No reference range established 4 - 14 Days: 100.0 - 717.0 ng/mL 15 Days - 5 Months: 14.0 - 647.0 ng/mL 6 Months - 11 Months: 8.0 - 182.0 ng/mL 1 - 4 Years: 5.0 - 100.0 ng/mL 5 - 13 Years: 14.0 - 79.0 ng/mL 14 - 19 Years: 6.0 - 67.0 ng/mL >/= 20 Years: 5.0 - 204.0 ng/mL Male: 0 - 3 Days: No reference range established 4 - 14 Days: 100.0 - 717.0 ng/mL 15 Days - 5 Months: 14.0 - 647.0 ng/mL 6 Months - 11 Months: 8.0 - 182.0 ng/mL 1 - 4 Years: 5.0 - 100.0 ng/mL 5 - 13 Years: 14.0 - 79.0 ng/mL 14 - 15 Years: 13.0 - 83.0 ng/mL 16 - 19 Years: 11.0 - 172.0 ng/mL >/= 20 Years: 22.0 - 275.0 ng/mL
279	CI
280	BCH BPH RHR THL	Fetal Fibronectin	Negative
281	BCH BPH RHR THL
282	RHC	Fetal Hgb Flow Marker	< 0 %
283	RHC
284	RHC THL	Fibrin Degradation Products (FDP)	< 5 ug/mL
285	RHC THL
286	BCH BPH RHC RHR THL	Fibrinogen	196 - 490 mg/dL
287	BCH BPH RHC RHR THL
288	GMH	Folate	4.8 - 24.2 ng/mL
289	RHC
290	CI	Folate	7.0 - 31.4 ng/mL
291	CI
292	RHC	Follicle-Stimulating Hormone (FSH)	Male: 0 - 11 Months: 0.1 - 3.2 mIU/mL 1 - 8 Years: 0.2 - 2.1 mIU/mL 9 - 11 Years: 0.4 - 4.2 mIU/mL 12 - 18 Years: 0.9 - 7.1 mIU/mL >/= 19 Years: 1.5 - 12.4 mIU/mL Female: 0 - 11 Months: 1.6 - 19.0 mIU/mL 1 - 8 Years: 0.7 - 5.8 mIU/mL 9 - 11 Years: 0.5 - 7.6 mIU/mL 12 - 18 Years: 0.9 - 9.1 mIU/mL >/= 19 Years: 1.5 - 12.4 mIU/mL Normally Menstruating Females: Follicular Phase: 3. 5 -12.5 mIU/mL Ovulation: 4.7 - 21.5 mIU/mL Luteal: 1.7 - 7.7 mIU/mL Postmenopause: 25.8 - 134.8 mIU/mL
293
294	BEH GMH LCH OMH RHC	Fractional Excretion of Sodium	<1.0% is indicative of prerenal azotemia. >1.5% is indicative of acute tubular necrosis.
295	RHC
296	RHC	G-6-PD Screen	Normal
297	RHC
298	RHC	Gamma Glutamyltransferase (GGT)	Male: 8 - 61 IU/L Female: 5 - 36 IU/L
299	RHC
300	BCH BPH RHC THL	Gentamicin	TROUGH: 0 - 2 Months < 1.1 ug/mL >/= 3 Months < 2.0 ug/mL PEAK: 5.0 - 10.0 ug/mL RANDOM: 2.0 - 10.0 ug/mL
301	BCH BPH RHC THL
302	RHC	GI Panel by PCR	Not Detected
303	RHC
304	RHC	Giardia Antigen	Negative
305	RHC
306	BCH BPH RHC RHR THL	Glomerular Filtration Rate (GFR)	>/= 2 Years: > 59 mL/min/1.73 m2* *Interpret with caution, quantification of eGFR values below 60 mL/min/1.73 sq meter has more clinical implications for classification of kidney function than values above this level. GFR and GFRA are calculated using the CKD-EPI equation for >18 Years and Bedside Schwartz for 2-18 Years.
307	BCH BPH RHC RHR THL
308	RHC	Gliadin Deamidated Peptide Ab, IgA EliA	< 7.0 U/mL Interpretive Data: Negative 0.1-6.9 U/mL Equivocal 7.0-10.0 U/mL Positive >10.0 U/mL
309	RHC
310	RHC	Gliadin Deamidated Peptide Ab, IgG EliA	< 7.0 U/mL Interpretive Data: Negative 0.4-6.9 U/mL Equivocal 7.0-10.0 U/mL Positive >10.0 U/mL
311	RHC
312	RHC	Glomerular Basement Membrane Antibody (GBM) EliA	< 7.0 U/mL Normal < 7.0 U/mL Equivocal 7.0-10.0 U/mL Positive > 10.0 U/mL
313	RHC
314	BCH BPH RHC RHR THL	Glucose:	.
315	BCH BPH RHC RHR THL	Glucose, Serum	NICU Inpatient Locations: 51 - 60 mg/dL 0 - 23 Hours: 40 - 60 mg/dL 1 Day - 11 Months: 54 - 80 mg/dL >/= 1 Year: 70 - 99 mg/dL Interpretive Data: Fasting Glucose: Impaired Fasting 100 - 125 mg/dL Diagnostic of Diabetes Mellitus >/= 126 mg/dL Random Glucose: Reference: 70 - 139 mg/dL Diagnostic of Diabetes Mellitus >/= 200 mg/dL
316	CI	Glucose, Serum	0 - 23 Hours: 46 - 60 mg/dL 1 - 59 Days: 54 - 80 mg/dL 2 - 23 Months: 54 - 80 mg/dL >/= 1 Year 70 - 99 mg/dL
317	RHC THL	Glucose, Post Prandial:	< 180 for Non-Pregnant Adults with Diabetes </= 120 for Women with GDM
318	RHC THL	Glucose, 2 Hour Tolerance (non-gestational)	Fasting: 70 - 99 mg/dL Interpretive Data: 70 - 99 Normal 100 - 125 Increased risk for Diabetes >/= 126 Provisional Diagnosis of Diabetes 2 Hour: 70 - 139 mg/dL Interpretive Data: 70 - 139 Normal 140-199 Increased risk for Diabetes >/= 200 Provisional Diagnosis of Diabetes
319	RHC	Glucose, Gestational Screen	70 - 139 mg/dL
320	RHC	Glucose, Gestational Tolerance	The diagnosis of Gestational Diabetes Mellitus is made if at least two of the following four plasma glucose levels are met or exceeded: Fasting: < 95 mg/dL 1 Hour: < 180 mg/dL 2 Hour: < 155 mg/dL 3 Hour: < 140 mg/dL
321	BCH BPH RHC RHR THL	Glucose, CSF	0-10 Years: 60-80 mg/dL >/= 11 Years: 40-70 mg/dL
322	RHC	Glucose, Pleural Fluid	< 60 mg/dL is suggestive of an empyema or parapneumonic effusion.
323	BCH BPH RHC RHR THL	Glucose, Estimated Average	Refer to Glucose
324	BCH BPH RHC RHR THL
325	BCH BPH RHC	Group B Strep by Rapid PCR	Negative
326	BCH BPH RHC
327	RHC	Haptoglobin	0 - 14 Days: </= 12 mg/dL 15 Days - 11 Months: </= 238 mg/dL 1 - 11 Years: </= 176 mg/dL 12 - 18 Years: </= 193 mg/dL >/= 19 Years: 30 - 200 mg/dL
328	RHC
329	RHC	Hemoglobin A1C	< 5.7 % Interpretive Data: 5.7 - 6.4% At Risk for Diabetes Mellitus >/= 6.5% Diagnostic for Diabetes Mellitus For monitoring diabetic patients, it is recommended that glycemic goals are individualized following current American Diabetes Association (ADA) Standards of Care recommendations. If HbA1C results are not consistent with blood glucose monitoring results, interference should be considered. Blood transfusions may impact the HbA1c concentration in the patient sample.
330	RHC
331	GMH	Hemoglobin Electrophoresis	Hgb A1: 96.0 - 98.0 % Hgb A2: 1.5 - 4.0 % Hgb S: 0.0 % Hgb C: 0.0 % Other Hgb 1: 0.0 % Hgb F: 0 - 6 Days: 77.0 - 97.0 % 7 - 14 Days: 79.6 - 91.4 % 15 - 45 Days: 59.8 - 89.6 % 46 Days - 2 Months: 23.9 - 67.2 % 3 - 5 Months: 4.4 - 27.5 % 6 - 8 Months: 1.5 - 27.8 % 9 - 14 Months: 0.4 - 8.4 % 15 - 23 Months: 0.1 - 4.9 % 2 - 5 Years: 0.0 - 3.7 % 6 - 17 Years: 0.0 - 1.3 % >/= 18 Years: 0.0 %
332	RHC
333	GMH	Hemosiderin Laden Macrophage	Absent
334	GMH
335	GMH	Hepatitis A Antibody IgM	Non-Reactive
336	RHC
337	GMH	Hepatitis B Surface Antibody	< 8.5 mIU/mL: Negative - Individual is considered to be not immune to infection with HBV. >/= 8.5 to < 11.5 mIU/mL: Indeterminate - Unable to determine if anti-HBs is present at levels consistent with immunity. >/= 11.5 mIU/mL: Positive - Anti HBs concentration detected at > 10 mIU/mL. Individual is considered to be immune to infection with HBV.
338	RHC
339	GMH RHC	Hepatitis B Surface Antigen	Non-Reactive
340	RHC
341	GMH	Hepatitis B Core IgM	Non-Reactive
342	RHC
343	RHC	Hepatitis B Core Total Ab	Non-Reactive
344	RHC
345	GMH	Hepatitis C Antibody	Non-Reactive
346	RHC
347	RHC	Hepatitis C RNA by PCR, Quant	Not Detected
348	RHC
349	RHC	Herpes Simplex Virus (HSV), DNA by PCR	Not Detected
350	RHC
351	RHC	Herpes Simplex (HSV) Type 1 IgG	Negative
352	RHC
353	RHC	Herpes Simplex (HSV) Type 2 IgG	Negative
354	RHC
355	RHC	Herpes Simplex (HSV) I & II IgM	Negative
356	RHC
357	BCH BPH RHC THL	HIV Ag w/HIV1 & 2 Antibodies Screen	Non-Reactive
358	BCH BPH RHC THL
359	BCH BPH RHC THL	HIV Antibody	Non-Reactive
360	BCH BPH RHC THL
361	BCH BPH RHC THL	HIV Antigen	Non-Reactive
362	BCH BPH RHC THL
363	RHC	HIV-1 Viral Load RNA by PCR, Quantitative	Less than Limit of Dectection
364	RHC
365	RHC	Homocystine	Male: 5.5 - 16.2 umol/L Female: 4.4 - 13.6 umol/L
366	RHC
367	RHC	Human Papillomavirus (HPV)	Negative
368	RHC
369	BCH BPH RHC RHR THL	Immature Platelet Fraction (IPF)	1.1 - 6.1 %
370	BCH BPH RHC RHR THL
371	RHC	Immunoglobulin A (IgA)	0 Days - 11 Months: 0 - 10 mg/dL 1 - 2 Years: 0 - 80 mg/dL 3 - 5 Years: 10 - 140 mg/dL 6 - 13 Years: 30 - 220 mg/dL 14 - 18 Years: 40 - 290 mg/dL >/= 19 Years: 70 - 400 mg/dL
372	RHC
373	CI	Immunoglobulin A (IgA)	85 - 499 mg/dL
374	CI
375	RHC	Immunoglobulin E (IgE)	0 - 5 Months: <14 kU/L 6 - 11 Months: < 35 kU/L 1 - 2 Years: < 98 kU/L 3 - 3 Years: < 200 kU/L 4 - 6 Years: < 308 kU/L 7 - 8 Years: < 404 kU/L 9 - 12 Years: < 697 kU/L 13 - 15 Years: < 630 kU/L 16 - 17 Years: < 538 kU/L >/=18 Years: < 215 kU/L
376	RHC
377	GMH RHC	Immunoglobulin G (IgG)	0 - 14 Days: 320 - 1210 mg/dL 15 Days - 11 Months: 150 - 630 mg/dL 1 - 3 Years: 320 - 990 mg/dL 4 - 9 Years: 500 - 1170 mg/dL 10 - 18 Years: 600 - 1310 mg/dL >/=19 Years: 700 - 1600 mg/dL
378	RHC
379	CI	Immunoglobulin G (IgG)	610 - 1616 mg/dL
380	CI
381	RHC	Immunoglobulin M (IgM)	0 - 14 Days: 0 - 30 mg/dL 15 Days - 12 Weeks: 10 - 70 mg/dL 13 Weeks - 11 Months: 10 - 80 mg/dL 1 - 18 Years: Female: 40 - 180 mg/dL Male: 40 - 140 mg/dL >/= 19 Years: 40 - 230 mg/dL
382	RHC
383	CI	Immunoglobulin M (IgM)	35 - 242 mg/dL
384	CI
385	RHC	India Ink Prep	Negative
386	RHC
387	BCH BPH RHC	Influenza A/B PCR	Negative
388	BCH BPH RHC
389	BCH BPH RHC RHR THL	Influenzae A & B Antigen Screen	Negative
390	BCH BPH RHC RHR THL
391	RHC	Insulin, Fasting	3.0 - 19.0 uU/mL
392	RHC
393	RHC	Iron	Female: 0 - 13 Years: 29 - 137 ug/dL 14 - 18 Years: 33 - 170 ug/dL >/= 19 Years: 37 - 145 ug/dL Male: 0 - 13 Years: 29 - 137 ug/dL 14 - 18 Years: 43 - 176 ug/dL >/= 19 Years: 61 - 157 ug/dL
394	CI
395	CI	Iron	Female: 0 - 13 Years: 16 - 128 ug/dL >/= 14 Years: 50 - 170 ug/dL Male: 0 - 13 Years: 16 - 128 ug/dL >/= 14 Years: 65 - 175 ug/dL
396	RHC
397	RHC	Iron Binding Capacity (TIBC), Calculated	0 - 56 Days: 139 - 304 ug/dL 57 Days - 11 Months: 144 - 440 ug/dL 1 - 17 Years: 298 - 458 ug/dL >/= 18 Years: 250 - 450 ug/dL
398	CI
399	CI	Iron Binding Capacity (TIBC), Calculated	>/= 1 Year: 250 - 450 ug/dL
400
401	RHC	Kleihauer-Betke (KB) Stain	</= 0.10
402	RHC
403	BCH BPH RHC RHR THL	Lactate Dehydrogenase (LDH)	SERUM: 0 - 14 Days: </= 1128 IU/L 15 Days - 11 Months: </= 424 IU/L 1 - 9 Years: </= 305 IU/L 10 - 14 Years: Male: </= 270 IU/L Female: </= 260 IU/L 15 - 18 Years: </= 240 IU/L >/= 19 Years: Male: 135 - 225 IU/L Female: 135 - 214 IU/L BODY FLUID: Ratio of Pleural Fluid LDH to a simultaneously collected Serum Protein > 0.6 is predictive of an exudate.
404	BCH BPH RHC RHR THL
405	CI	Lactate Dehydrogenase (LDH)	0 - 14 Days: 309 - 599 IU/L 15 Days - 11 Months: 163 - 452 IU/L 1 - 9 Years: 192 - 321 IU/L 10 - 14 Years: Female: 157 - 272 IU/L Male: 170 - 283 IU/L 15 - 18 Years: 130 - 250 IU/L >/= 19 Years: 125 - 220 IU/L
406	CI
407	BCH BPH RHC RHR THL	Lactic Acid	PLASMA: 0.5 - 2.2 mmol/L CSF: 0 - 2 Days: 1.1 - 6.7 mmol/L 3 - 10 Days: 1.1 - 4.4 mmol/L 11 Days - 18 Years: 1.1 - 2.8 mmol/L >/= 19 Years: 1.1 - 2.4 mmol/L
408	BCH BPH RHC RHR THL
409	RHC	Legionella Antigen, Urine	Negative
410	RHC
411	RHC THL	Levetracitam (Keppra)	5.0 - 45.0 ug/mL
412	RHC THL
413	BCH BPH RHC RHR THL	Lipase	0 - 18 Years: </= 39 IU/L >/= 19 Years: 13 - 60 IU/L
414	BCH BPH RHC RHR THL
415	GMH	Lipid Laden Macrophage	Negative
416	GMH
417	RHC	Lipid Panel	Refer to ACC/AHA Clinical Practice Guidelines
418	RHC	Cholesterol	0 - 14 Days: Male: 44 - 109 mg/dL Female: 48 - 125 mg/dL 15 Days - 11 Months: 66 - 234 mg/dL 1 - 9 Years: 112 - 207 mg/dL 10 - 19 Years: Acceptable: < 170 mg/dL Borderline: 170 - 199 mg/dL Abnormal: >/=200 mg/dL >/= 20 Years: Desirable: < 200 mg/dL Borderline High: 200-239 mg/dL High >/= 240: mg/dL
419	RHC	Cholesterol/HDL Ratio	< 3.5
420	RHC	HDL	0 - 14 Days: 7 - 39 mg/dL 15 Days - 11 Months: </=75 mg/dL 1 - 3 Years: 28 - 65 mg/dL 4 - 9 Years: 31 - 77 mg/dL 10 - 19 years old: Acceptable: <110 mg/dL Borderline: 110-129 mg/dL High: >/=130 mg/dL >/=20 years old: Desirable: < 130 mg/dL Borderline: 130 - 159 mg/dL High Risk: >/= 160 mg/dL
421	RHC	LDL	0 - 11 Months: 13 - 173 mg/dL 1 - 9 Years: 47 - 128 mg/dL 10 - 19 Years: Acceptable: < 110 mg/dL Borderline: 110 - 129 mg/dL High: >/=130 mg/dL >/=20 Years: Desirable: <130 mg/dL Borderline: 130 - 159 mg/dL High Risk: >/=160 mg/dL
422	RHC	Non-HDL Cholesterol	0 - 11 Months: 28 - 202 mg/dL 1 - 9 Years: 69 - 166 mg/dL 10 - 19 Years: Acceptable: < 120 mg/dL Borderline: 120 - 144 mg/dL High: >/= 145 mg/dL >/= 20 Years: Optimal: < 130 mg/dL Borderline High: 130 - 159 mg/dL High: 160 - 189 mg/dL Very High: > 190 mg/dL
423	BCH BPH RHC THL	Triglycerides	0 - 9 Years: Acceptable < 75 mg/dL Borderline 75 - 99 mg/dL Abnormal: >/= 100 mg/dL 10 - 19 Years: Acceptable: < 90 mg/dL Borderline: 90 - 129 mg/dL Abnormal: >/= 130 mg/dL >/= 20 Years: Acceptable: < 150 mg/dL Borderline: 150 - 199 mg/dL High: 200 - 499 mg/dL Very High: >/= 500 mg/dL
424	RHC	VLDL	< 40 mg/dL
425	RHC
426	BCH BPH RHR THL	Lithium	0.6 - 1.2 mmol/L
427	BCH BPH RHR THL
428	RHC	Low Molecular Weight Heparin (LMWH)	Once daily dosing: 1.00 - 2.00 IU/mL Twice daily dosing: 0.60 - 1.00 IU/mL Prophylactic range: 0.20 - 0.50 IU/mL
429	RHC
430	RHC	Luteinizing Hormone (LH)	Male: 0 - 5 Months: </= 6.2 mIU/mL 6 Months - 10 Years: </= 1.3 mIU/mL 11 - 13 Years: </= 2 mIU/mL 14 - 18 Years: 1.3 - 8.4 mIU/mL >/= 19 Years: 1.7 - 8.6 mIU/mL Female: 0 - 5 Months: </=8.2 mIU/mL 6 Months - 10 Years: </=1.3 mIU/mL 11 - 13 Years: </=10 mIU/mL 14 - 18 Years: 0.4-25 mIU/mL >/= 19 Years: Mid-Cycle/Ovulation: 14 - 95.6 mIU/mL Luteal: 1 - 11.4 mIU/mL Postmenopausal (w/o Hormone Therapy): 7.7 - 58.5 mIU/mL
431	RHC
432	BCH BPH CI RHC RHR THL	Magnesium	0 - 20 Years: 1.5 - 2.3 mg/dL >/= 21 Years: 1.6 - 2.6 mg/dL
433	BCH BPH RHC RHR THL
434	RHC	Malaria	Screan: Negative % Parasitemia: 0 %
435	RHC
436	RHC	Meningitis/Enchephalitis Panel by PCR, CSF	Not Detected
437	RHC
438	BCH BPH RHC	Methicillin-resistant staphylococcus aureus (MRSA) PCR	Negative
439	BCH BPH RHC
440	RHC	Methotrexate Level	Interpretive Data: Methotrexate serum levels depend on indication for use, dosage, mode of administration, treatment regimen, individual pharmacokinetics, metabolism and other clinical factors. 24 hr: 5 - 10 umol/L 48 hr: 0.5 - 1.0 umol/L 72 hr: < 0.2 umol/L
441	RHC
442	RHC	Microalbumin, Urine	RANDOM: Concentration: < 30 mg/L TIMED: Output per 24 Hours: Normal: < 30 mg/24hr Microalbuminuria: 30 - 299 mg/24hr Macro clinical albuminuria: >/= 300 mg/24hr Output per Minute Normal: < 20 ug/min Microalbuminuria: 20 - 199 ug/min Macro clinical albuminuria: >/= 200 ug/min
443	RHC
444	RHC	Microalbumin/Creatinine Ratio, Urine	< 30 mg/g Normal to Mildly Increased: < 30 mg/g Moderately Increased: 30 - 299 mg/g Severely Increased: >/= 300 mg/g Two of three specimens of microalbumin/creatinine ratio should be abnormal before considering a patient to have high or very high albuminuria.
445	RHC
446	BCH BPH RHC THL	Monotest	Negative
447	BCH BPH RHC THL
448	RHC	Myeloperoxidase IgG (MPO) Antibody	< 3.5 U/mL Interpretive Data: < 3.5 Normal 3.5-5.0 Equivocal > 5.0 Positive The specificity of anti-MPO for systemic vasculitis and/or idiopathic crescentic glomerulonephritis is as high as 95% when groups of patients with renal disorders and diseases related to vasculitis are studied. However, MPO antibodies occur incidentally in other diseases such as drug induced lupus erythematosus, rheumatoid arthritis and inflammatory bowel disease.
449	RHC
450	RHC	Mycobacterium Tuberculosis by PCR	Not Detected
451	RHC
452	RHC	Mycoplasma pneumonia DNA	Not Detected
453	RHC
454	RHC	Myoglobin	Male: < 93 ng/mL Female: < 81 ng/mL
455	RHC
456	RHC	Neisseria gonorrhoeae (GC), NAAT	Negative
457	RHC
458	BCH BPH RHC THL	Occult Blood, Fecal/Gastric/Vomitus	Negative
459	BCH BPH RHC THL
460	BCH BPH RHC RHR THL	Osmolality	SERUM: 270 - 295 mOsm/kgH2O URINE: 50 - 1200 mOsm/kgH2O Interpretive Data: Varies significantly with hydration Average fluid intake 300 - 900 After 12 Hr fluid restriction > 850
461	BCH BPH RHC RHR THL
462	RHC THL	Parathyroid Hormone (PTH), Intact	15 - 65 pg/mL
463	RHC THL
464	RHC THL	Parathyroid Hormone (PTH), Baseline	15 - 65 pg/mL
465	RHC THL
466	RHC RHR THL	Parathyroid Hormone (PTH) Intraoperative	<50% of baseline value
467	RHC RHR THL
468	RHC	Phenobarbital Therapeutic Range	15 - 40 ug/mL
469	RHC
470	BCH BPH RHC RHR THL	Phosphorus	0 - 14 Days: 5.3 - 9.8 mg/dL 15 Days - 11 Months: 4.6 - 7.9 mg/dL 1 - 4 Years: 4.1 - 6.4 mg/dL 5 - 12 Years: 4.0 - 5.6 mg/dL 13 - 15 Years: Male: 3.5 - 5.8 mg/dL Female: 3.1 - 5.3 mg/dL 16 - 18 Years: 2.9 - 4.8 mg/dL >/=19 Years: 2.5 - 4.5 mg/dL
471	BCH BPH RHC RHR THL
472	CI	Phosphorus	0 - 14 Days: 5.6 - 9.9 mg/dL 15 Days - 11 Months: 4.8 - 8.4 mg/dL 1 - 4 Years: 4.3 - 6.8 mg/dL 5 - 12 Years: 4.1 - 5.9 mg/dL 13 - 15 Years: Female: 3.2 - 5.5 mg/dL Male: 3.5 - 6.2 mg/dL 16 - 18 Years: 2.9 - 5.0 mg/dL >/= 19 Years: 2.3 - 4.7 mg/dL
473	CI
474	RHC	Pinworm Prep/Exam	Not Present
475	RHC
476	RHR THL	Platelet Function Screen (PFS)	ASPIRIN: 350 - 549 sec P2Y12: 50 - 208 sec SCREEN: Col/Epi: 78 - 177 sec Col/ADP: 50 – 102 sec
477	RHR THL
478	RHC	Post Vasectomy Semen Analysis	Post Vas Total Sperm: Absent Post Vas Semen Volume: 0.5 - 5.0 mL Post Vas Nonmotile Sperm: < 1% Post Vas Motile Sperm: < 1%
479	RHC
480	BCH BPH CI RHC RHR THL	Potassium (K+)	SERUM/PLASMA: 0 - 27 Days: 3.7 - 5.9 mmol/L 28 Days - 1 Year: 4.1 - 5.3 mmol/L 2 - 17 Years: 3.4 - 4.7 mmol/L >/= 18 Years: 3.5 - 5.1 mmol/L URINE: Random: Interpretive Data: No Reference Ranges Established Timed: 25.0 - 125.0 mmol/24 hr Interpretive Data: Varies significantly with hydration and diet.
481	BCH BPH RHC RHR THL
482	RHC	Prealbumin	0 - 14 Days: </= 1.0 mg/dL 15 Days - 11 Months: 4.0 - 24.0 mg/dL 1 - 4 Years: 11.0 - 23.0 mg/dL 5 - 12 Years: 13.0 - 26.0 mg/dL 13 - 15 Years: 17.0 - 31.0 mg/dL 16 - 17 Years: Female: 16.0 - 33.0 mg/dL Male: 20.0 - 35.0 mg/dL >/= 18 Years: 20.0 - 40.0 mg/dL
483	RHC
484	BCH BPH RHR THL	Procalcitonin	< 0.10 ng/mL Interpretive Data: < 0.5: On the first day of ICU admission is associated with a low risk for progression to severe sepsis and/or septic shock > 2.0: On the first day of ICU admission is associated with a high risk for progression to severe sepsis and/or septic shock Procalcitonin values are physiologically increased in neonates during the first two Days of life. The reference range applies from three Days after birth.
485	BCH BPH RHR THL
486	RHC	Progesterone	Male: < 0.2 ng/mL Female: Cycle Phase: Follicular: < 0.2 ng/mL Ovulation: 0.2 - 4.1 ng/mL Luteal: 4.1 - 14.5 ng/mL Menopausal: < 0.2 ng/mL Healthy Pregnant Females: 1st Trimester: 11.0 - 44.3 ng/mL 2nd Trimester: 25.4 - 83.4 ng/mL 3rd Trimester: 58.7 - 214.0 ng/mL
487	RHC
488	GMH	Prolactin	0 - 30 Days: 1.1 - 470.0 ng/mL 1 - 11 Months: 5.2 - 60.0 ng/mL 1 - 18 Years: 3.0 - 25.0 ng/mL >/= 19 Years: Male: 4.0 - 15.2 ng/mL Female (Non-Pregnant): 4.79 - 23.3 ng/mL
489	RHC
490	RHC	Protein C Activity	70 - 161 %
491	RHC
492	RHC	Protein S Activity	70 - 140 %
493	RHC
494	BCH BPH RHC RHR THL	Protein, Total	SERUM: 0 -14 Days: 5.1 - 8.0 g/dL 15 Days - 11 Months: 4.3 - 6.9 g/dL 1 - 5 Years: 5.9 - 7.3 g/dL 6 - 8 Years: 6.2 - 7.5 g/dL 9 - 18 Years: 6.3 - 7.8 g/dL >/=19 Years: 6.4 - 8.3 g/dL URINE: Concentration: No Established Reference Range Timed: < 300 mg/24 hr At Rest 50 - 80 mg/24 hr BODY FLUID: Interpretive Data: Pleural and Pericardial: Transudate effusions have a low concentration of Total Protein. Exudate effusions have a high concentration of Total Protein. Serous fluid Total Protein values >/=3.0 g/dL separate exudates from transudates. A ratio of serous fluid total protein to a simultaneously collected serum protein of >/=0.5 is predictive of an exudate. CSF: 0 - 30 Days: 20.0 - 80.0 mg/dL >/= 1 Month: 15.0 - 45.0 mg/dL
495	BCH BPH RHC RHR THL
496	CI	Protein, Total	0 - 14 Days: 5.3 - 8.3 g/dL 15 - 11 Months: 4.4 - 7.1 g/dL 1 - 5 Years: 6.1 - 7.5 g/dL 6 - 8 Years: 6.4 - 7.7 g/dL 9 - 18 Years: 6.5 - 8.1 g/dL >/= 19 Years: 6.2 - 8.3 g/dL
497	CI
498	BCH BPH RHC THL	Protein/Creatinine Ratio, Urine	< 0.2 mg/mg
499	BCH BPH RHC THL
500	CI	Protein Electrophoresis, Serum	Albumin: 3.00 - 5.05 g/dL Alpha 1 Globulin: 0.13 - 0.36 g/dL Alpha 2 Globulin: 0.57 - 1.22 g/dL Beta: 0.69 - 1.33 g/dL Gamma Globulin: 0.63 - 2.00 g/dL Alb/Glob Ratio: 0.92 - 1.86
501	RHC
502	BCH BPH RHC RHR THL	Prothrombin Time (PT)/INR	PT: 11.8 - 15.0 seconds INR: 0.8 - 1.2
503	BCH BPH RHC RHR THL
504	RHC	PT Mixing Study	No Inhibitor Detected
505	RHC
506	BCH BPH RHC RHR THL	Partial Thromboplastin Time (PTT)	24 - 36 seconds
507	BCH BPH RHC RHR THL
508	RHC	PTT Mixing Study	No Inhibitor Detected
509	RHC
510	CI	PSA	TOTAL: < 4.1 ng/mL
511	CI
512	RHC	Quantiferon TB Plus	Negative
513	RHC
514	RHC	Respiratory Panel by PCR	.
515	RHC	Adenovirus	Not Detected
516	RHC	Bordetella Pertussis	Not Detected
517	RHC	Bordetella Parapertussis	Not Detected
518	RHC	Chlamydophilia Pneumoniae	Not Detected
519	RHC	Coronavirus 229E	Not Detected
520	RHC	Coronavirus HKU1	Not Detected
521	RHC	Coronavirus NL63	Not Detected
522	RHC	Coronavirus OC43	Not Detected
523	RHC	Coronavirus SARS-CoV-2	Not Detected
524	RHC	Human Metapneumovirus	Not Detected
525	RHC	Human Resp Syncytial Virus	Not Detected
526	RHC	Influenza Virus A	Not Detected
527	RHC	Influenza A/H1 2009	Not Detected
528	RHC	Influenza A/H1	Not Detected
529	RHC	Influenza A/H3	Not Detected
530	RHC	Influenza Virus B	Not Detected
531	RHC	Mycoplasma Pneumoniae	Not Detected
532	RHC	Parainfluenza Virus 1	Not Detected
533	RHC	Parainfluenza Virus 2	Not Detected
534	RHC	Parainfluenza Virus 3	Not Detected
535	RHC	Parainfluenza Virus 4	Not Detected
536	RHC	Rhino/Entero	Not Detected
537	RHC
538	BCH BPH RHC RHR THL	Respiratory Syncytial Virus (RSV) Antigen	Negative
539	BCH BPH RHC RHR THL
540	BCH BPH RHC RHR THL	Reticulocyte Count (Automated)	RELATIVE 0 - 3 Days: 3.47 - 5.40 % 4 - 30 Days: 1.06 - 2.37 % 31 - 60 Days: 2.12 - 3.47 % 61 Days - 5 Months: 1.55 - 2.70 % 6 Months - 1 Year: 0.99 - 1.82 % 2 - 5 Years: 0.82 - 1.45 % 6 - 11 Years: 0.98 - 1.94 % 12 - 17 Years: 0.90 - 1.49 % >/= 18 Years: Male: 0.51 - 1.81 % Female: 0.50 - 1.70 % ABSOLUTE 0 - 3 Days: 0.15 - 0.22 Mil/uL 4 - 30 Days: 0.05 - 0.11 Mil/uL 31 - 60 Days: 0.05 - 0.08 Mil/uL 61 Days - 5 Months: 0.05 - 0.09 Mil/uL 6 Months - 1 Year: 0.04 - 0.11 Mil/uL 2 - 18 Years: 0.04 - 0.07 Mil/uL >/= 18 Years: Male: 0.03 - 0.10 Mil/uL Female: 0.02 - 0.08 Mil/uL IRF 1 - 3 Days: 30.50 - 35.10 % 4 - 30 Days: 14.50 - 24.60 % 31 - 60 Days: 19.10 - 28.90 % 2 - 5 Months: 13.40 - 23.30 % 6 - 23 Months: 11.40 - 25.80 % 2 - 5 Years: 8.40 - 21.70 % 6 - 11 Years: 8.90 - 24.10 % 12 - 17 Years: 9.00 - 18.70 % >/= 18 Years: Male: 9.30 - 17.40 % Female: 2.30 - 13.40 % HEMOGLOBIN EQUIVALENT Male: 0 - 5 Months: 27.6 - 38.7 pg 6 - 23 Months: 28.7 - 35.7 pg 2 - 5 Years: 27.7 - 37.8 pg 6 - 11 Years: 32.4 - 37.6 pg 12 - 17 Years: 30.3 - 40.4 pg >/= 18 Years: 36.0 - 38.6 pg Female: 0 - 5 Months: 29.2 - 37.5 pg 6 - 23 Months: 30.1 - 35.7 pg 2 - 5 Years: 29.3 - 37.3 pg 6 - 11 Years: 30.4 - 39.7 pg 12 - 17 Years: 29.9 - 38.4 pg >/= 18 Years: 30.6 - 40.7 pg
541	BCH BPH RHC RHR THL
542	RHC	Rheumatoid Factor (RF)	< 14 IU/mL
543	RHC
544	RHC THL	Rotavirus Antigen	Negative
545	RHC THL
546	BCH BPH RHC	Strep Group A Screen	Negative
547	BCH BPH RHC
548	BCH BPH RHR THL	Salicylate	< 30 mg/dL
549	BCH BPH RHR THL
550	RHC	Serine Protease 3 (PR-3) Antibody	< 2.0 U/mL Interpretive Data: < 2.0 Normal 2.0-3.0 Equivocal > 3.0 Positive Anti-PR3 antibodies are highly specific for GPA. However, PR3 antibodies are reported in infective disorders in monoclonal gammopathy and in a few cases of malignancy without signs of secondary vasculitis.
551	RHC
552	RHC	Sex Hormone Binding Globulin (SHBG)	Male: 11.2 - 78.1 nmol/L Female: 11.7 - 137.2 nmol/L
553	RHC
554	RHC	Sickle Cell Screen	Negative
555	RHC
556	RHC	Sirolimus	5.0 - 15.0 ng/mL
557	RHC
558	BCH BPH CI RHC RHR THL	Sodium, Serum	0 - 26 Days: 133 - 146 mmol/L 27 - 1 Year: 139 - 146 mmol/L 2 - 17 Years: 138 - 145 mmol/L >/= 18 Years 136 - 145 mmol/L
559	BCH BPH CI RHC RHR THL
560	BCH BPH RHC RHR THL	Sodium, Urine	Random: No reference ranges established. Timed: Male: 6 - 10 Years: 41 - 115 mmol/24hr 10 - 14 Years 63 - 177 mmol/24hr >/= 14 Years: 40 - 220 mmol/24hr Female: 6 - 10 Years: 20 - 69 mmol/24hr 10 - 14 Years 48 - 168 mmol/24hr >/= 14 Years: 40 - 220 mmol/24hr Interpretive Data: Varies significantly with hydration and diet.
561	BCH BPH RHC RHR THL
562	GMH	Special Fungal/Pneumocystis Stain	Negative
563	GMH
564	RHC	Strep pneumoniae Antigen, Urine/CSF	Negative
565	RHC
566	RHC	Syphilis Testing	.
567	RHC	Treponema Antibody	Non-Reactive
568	RHC	Rapid Plasma Reagin (RPR)	Non-Reactive
569	RHC	Treponema Particle Agglutination	Non-Reactive
570	RHC	VDRL, CSF	Non-Reactive
571	RHC
572	RHC	T3, Free	Male and Female: 4 Days - 11 Months: 2.32 - 4.87 pg/mL 1 - 11 Years: 2.79 - 4.42 pg/mL 12 - 14 Years: Male: 2.89 - 4.33 pg/mL Female: 2.50 - 3.95 pg/mL 15 - 18 Years: Male: 2.25 - 3.85 pg/mL Female: 2.31 - 3.71 pg/mL >/= 19 Years: 1.71 - 3.71 pg/mL
573	RHC
574	RHC	T3, Total	4 Days - 11 Months: 85 - 234 ng/dL 1 - 11 Years: 113 - 189 ng/dL 12 - 14 Years: 98 - 176 ng/dL 15 - 16 Years: 93 - 156 ng/dL 17 - 18 Years: 90 -168 ng/dL >/= 19 Years: 58 - 159 ng/dL
575	RHC
576	BCH BPH RHC THL	T4, Free	0 - 30 Days: 1.24 - 3.89 ng/dL 1 - 11 Months: 1.09 - 1.71 ng/dL 1 - 18 Years: 1.01 - 1.63 ng/dL >/= 19 Years: 0.93 - 1.70 ng/dL
577	BCH BPH RHC THL
578	RHC	T4, Total	4.87 - 11.72 ug/dL
579	RHC
580	RHC	Tacrolimas (FK506)	5.0 - 20.0 ng/mL
581	RHC
582	RHR	Thromboelastogram (TEG)	.
583	RHR	TEG, Basic	R Plain 5.0 - 10.0 min K Plain 1.0 - 3.0 min Angle Plain 53.0 - 72.0 deg MA Plain 50.0 - 70.0 mm LY30 Plain 0.0 - 8.0 % R Heparin Treated 5.0 - 10.0 min K Heparin Treated 1.0 - 3.0 min Angle Heparin Treated 53.0 - 72.0 deg MA Heparin Treated 50.0 - 70.0 mm LY30 Heparin Treated 0.0 - 8.0 %
584	RHR	TEG, Accelerated	R Rapid Plain 0.4 - 0.7 min K Rapid Plain 0.6 - 2.3 min Angle Rapid Plain 64.0 - 80.0 deg MA Rapid Plain 52.0 - 71.0 mm LY30 Rapid Plain 0.0 - 8.0 % TEG ACT Plain 86.0 - 118.0 sec R Rapid Heparin Treated 0.4 - 0.7 min K Rapid Heparin Treated 0.6 - 2.3 min Angle Rapid Heparin Treated 64.0 - 80.0 deg MA Rapid Heparin Treated 52.0 - 71.0 mm LY30 Rapid Heparin Treated 0.0 - 8.0 % TEG ACT Heparin Treated 86.0 - 118.0 sec
585	RHR	TEG with Platelet Mapping	R Plain 5.0 - 10.0 min K Plain 1.0 - 3.0 min Angle Plain 53.0 - 72.0 deg MA Plain 50.0 - 70.0 mm LY30 Plain 0.0 - 8.0 % R Heparin Treated 5.0 - 10.0 min K Heparin Treated 1.0 - 3.0 min Angle Heparin Treated 53.0 - 72.0 deg MA Heparin Treated 50.0 - 70.0 mm LY30 Heparin Treated 0.0 - 8.0 %
586	RHR	TEG Functional Fibrinogen	MA Functional Fibrinogen 11.5 - 31.6 mm TEG Functional Fibrinogen 210.6 - 576.4 mg/dL
587	GMH RHR	TEG Global Hemostasis	R-TEG 4.6 - 9.1 minutes K-TEG 0.8 - 2.1 minutes Angle-TEG 63.0 - 78.0 degrees MA-TEG 52.0 - 69.0 mm MA-TEG, Rapid 52.0 - 70.0 mm R-TEG, w/Hep 4.3 - 8.3 minutes MA Functional Fibrinogen 15.0 - 32.0 mm FLEV 278.0 - 581.0 mg/dL
588	GMH RHR	TEG Global Hemostasis w Lysis	R-TEG 4.6 - 9.1 minutes MA-TEG, Rapid 52.0 - 70.0 mm MA Functional Fibrinogen 15.0 - 32.0 mm LY30-TEG <= 2.6 %
589	GMH RHR
590	RHC	Testosterone	Male: 21 - 49 Years: 240 - 871 ng/dL >/= 50 Years: 221 - 716 ng/dL Female: Premenopausal 21 - 49 Years: 14 - 53 ng/dL Postmenopausal >/= 50 Years: 12 - 36 ng/dL
591	RHC
592	RHC	Theophylline	5.0 - 20.0 ug/mL
593	RHC
594	RHC	Thrombin Clot Time	13.0 - 21.0 seconds
595	RHC
596	RHC	Thyroglobulin Antibody	< 4.1 IU/mL
597	RHC
598	RHC	Thyroid Peroxidase Autoantibodies (TPO)	< 5.6 IU/mL
599	RHC
600	RHC	Tissue Transglutaminase (TTG), IgA	< 7.0 EliA u/mL Interpretive Data: 0.1-6.9: Negative 7.0-10.0: Equivocal >1 0.0: Positive
601	RHC
602	GMH OMH RHC	Tobramycin	TROUGH: 0 - 2 Months < 1.1 ug/mL >/= 3 Months < 2.0 ug/mL PEAK: 5.0 - 10.0 ug/mL RANDOM: 2.0 - 10.0 ug/mL
603	RHC THL
604	RHC	Toxoplasma IgG	Negative
605	RHC
606	RHC	Transferrin	0 - 56 Days: 111 - 243 mg/dL 57 Days - 11 Months: 115 - 352 mg/dL 1 - 17 Years: 238 - 366 mg/dL >/= 18 Years 200 - 360 mg/dL
607	RHC
608	CI	Transferrin	180 - 365 mg/dL
609	CI
610	RHC	Transferrin Saturation	Male: 20 - 50 % Female: 15 - 50 %
611	RHC
612	CI	Transferrin Saturation	20 - 50 %
613	CI
614	RHC	Trichomonas Vaginalis, NAAT	Negative
615	RHC
616	BCH BPH RHC RHR THL	Troponin I	< 0.03 ng/mL
617	BCH BPH RHC RHR THL
618	BCH BEH BPH GMH GrMH HMH LCH NGH OMH PWH RHC THL	Troponin T	0 - 5 Months: < 94 ng/L 6 - 11 Months: < 22 ng/L 1 - 18 Years: Male: < 15 ng/L Female: < 12 ng/L >/= 19 Years: < 20 ng/L
619	BCH BEH BPH GMH GrMH HMH LCH NGH OMH PWH RHC THL
620	BCH BPH RHC	Thyroid Stimulating Hormone (TSH)	0 - 30 Days: 1.230 - 27.200 uIU/ml 1 - 11 Months: 1.030 - 6.800 uIU/ml 1 - 14 Years: 1.120 - 5.010 uIU/ml 15 - 18 Years: 0.680 - 4.090 uIU/ml >/= 19 Years: 0.270 - 4.200 uIU/ml
621	BCH BPH RHC
622	CI	Thyroid Stimulating Hormone (TSH)	0.40 - 5.60 uIU/mL
623	CI
624	BCH BPH RHC THL	Total Volume, Urine	Varies significantly with hydration. 0 - 2 Days: 30 - 60 mL/24 hr 3 - 9 Days: 100 - 300 mL/24 hr 10 Days - 1 Month: 250 - 450 mL/24 hr 2 - 11 Months: 400 - 500 mL/24 hr 1 - 2 Years: 500 - 600 mL/24 hr 3 - 4 Years: 600 - 700 mL/24 hr 5 - 7 Years: 650 - 1000 mL/24 hr 8 - 14 Years: 800 - 1400 mL/24 hr 15 - 59 Years: Male: 800 - 1800 mL/24 hr Female: 600 - 1600 mL/24 hr >/= 60 Years: 250 - 2400 mL/24 hr
625	BCH BPH RHC THL
626	RHC RHR	Unfractionated Heparin Anti-Xa (UFH)	0.30 - 0.70 IU/mL
627	RHC RHR
628	BCH BPH RHC RHR THL	Urea Nitrogen, Blood (BUN)	0 - 7 Days: 3 - 25 mg/dL 8 Days - 11 Months: 4 - 19 mg/dL 1 - 18 Years: 5 - 18mg/dL 19 - 59 Years: 6 - 20 mg/dL 60 - 90 Years: 8 - 23 mg/dL >/= 91 Years: 10 - 31 mg/dL
629	BCH BPH RHC RHR THL
630	CI	Urea Nitrogen, Blood (BUN)	0 - 14 Days: 3 - 22 mg/dL 15 Days - 11 Months: 4 - 17 mg/dL 1 - 9 Years: 9 - 22 mg/dL 10 - 18 Years: 7 - 20 mg/dL 19 - 49 Years: Female: 7 - 20 mg/dL Male: 9 - 21 mg/dL >/= 50 Years: Female: 7 - 20 mg/dL Male: 8 - 26 mg/dL
631	CI
632	BCH BPH RHC RHR THL	Urea Nitrogen, Urine	Random: No Reference Ranges Established Timed: 3,000-5,000 mg/6 Hrs 12,000 - 20,000 mg/24 Hrs
633	BCH BPH RHC RHR THL
634	BCH BPH RHC RHR THL	Uric Acid	0 - 14 Days: 2.7 - 12.0 mg/dL 15 Days - 11 Months: 1.5 - 6.2 mg/dL 1 - 11 Years: 1.7 - 4.7 mg/dL 12 - 18 Years: Female: 2.5 - 5.7 mg/dL Male: 2.5 - 7.5 mg/dL >/= 19 Years: Male: 3.4 - 7.0 mg/dL Female: 2.4 - 5.7 mg/dL
635	BCH BPH RHC RHR THL
636	CI	Uric Acid	0 - 14 Days: 2.8 - 11.9 mg/dL 15 Days - 11 Months: 1.6 - 6.3 mg/dL 1 - 11 Years: 1.8 - 4.9 mg/dL 12 - 18 Years: Female: 2.6 - 5.9 mg/dL Male: 2.6 - 7.6 mg/dL >/= 19 Years: Female: 2.6 - 6.0 mg/dL Male: 3.5 - 7.2 mg/dL
637	CI
638	BCH BPH CI RHC RHR THL	Urinalysis	.
639	BCH BPH CI RHC RHR THL	Urinalysis Chem Screen	.
640	BCH BPH CI RHC RHR THL	Appearance	Clear, Slightly Hazy, Hazy
641	BCH BPH CI RHC RHR THL	Spec Gravity	1.003 - 1.035
642	BCH BPH CI RHC RHR THL	Ph	4.6 - 8.0
643	BCH BPH CI RHC RHR THL	Glucose	Negative
644	BCH BPH CI RHC RHR THL	Protein	Negative
645	BCH BPH CI RHC RHR THL	Ketone	Negative
646	BCH BPH CI RHC RHR THL	Bilirubin	Negative
647	BCH BPH CI RHC RHR THL	Blood	Negative
648	BCH BPH CI RHC RHR THL	Nitrite	Negative
649	BCH BPH CI RHC RHR THL	Urobilinogen	< 2.0 mg/dL
650	BCH BPH CI RHC RHR THL	Leuk Esterase	Negative
651	BCH BPH RHC RHR THL	Urinalysis Microscopic Exam	.
652	BCH BPH RHC RHR THL	WBC’s	0 - 5 /HPF
653	BCH BPH RHC RHR THL	RBC’s	0 - 2 /HPF
654	BCH BPH RHC RHR THL	Epithelial Cells (Squamous)	</= 8 /LPF
655	BCH BPH RHC RHR THL	Renal Epithelial Cells	0 /LPF
656	BCH BPH RHC RHR THL	Bacteria	< Moderate
657	BCH BPH RHC RHR THL	Hyaline Casts	0 - 3 /LPF
658	BCH BPH RHC RHR THL	Cast	0 /LPF
659	BCH BPH RHC RHR THL
660	CI	Urinalysis Microscopic Exam	.
661	CI	WBC’s	0 - 3 /HPF
662	CI	RBC’s	0 - 2 /HPF
663	CI	Epithelial Cells (Squamous)	0 - 5 /LPF
664	CI	Renal Epithelial Cells	0 /LPF
665	CI	Bacteria	None Seen
666	CI	Hyaline Casts	0 - 2 /LPF
667	CI
668	RHC	Vaginitis Panel by PCR	.
669	RHC	Trichomonas	Negative
670	RHC	Gardnerella	Negative
671	RHC	Candida	Negative
672	RHC
673	BCH BPH RHC RHR THL	Valproic Acid	TOTAL: 50 - 125 ug/mL FREE: 6 - 22 ug/mL FREE %: 5 - 18 %
674	BCH BPH RHC RHR THL
675	BCH BPH RHC RHR THL	Vancomycin	TROUGH: 10.0 - 20.0 ug/mL PEAK: 30.0 - 50.0 ug/mL RANDOM: 5.0 - 40.0 ug/mL
676	BCH BPH RHC RHR THL
677	RHC	Varicella Zoster, IgM	Negative
678	RHC
679	GMH	Vitamin B12	232 - 1245 pg/mL
680	RHC
681	CI	Vitamin B12	180 - 914 pg/mL
682	CI
683	RHC	Vitamin D 25-Hydroxy	30 - 100 ng/mL Interpretive Data: < 20: Deficiency 20-29: Insufficiency 30-100: Sufficiency > 150: Possible Toxicity
684	RHC
685	BCH BPH RHC RHR THL	Wet Prep (Manual)	None Seen/Not Present
686	BCH BPH RHC RHR THL
687	POC	POINT OF CARE:
688	BCH BPH RHR	ACT-celite	74 - 152 seconds
689	BCH BPH RHR
690	BCH BPH RHR	ACT-Kaolin	74 - 152 seconds
691	BCH BPH RHR
692	BCH BPH RHR	BUN	Male: 0 - 14 Days: 3 - 22 mg/dL 15 Days - 11 Months: 4 - 17 mg/dL 1 - 9 Years: 9 - 22 mg/dL 10 - 18 Years: 7 - 20 mg/dL 19 - 49 Years: 9 - 21 mg/dL >/= 50 Years 8 - 26 mg/dL Female: 0 - 14 Days: 3 - 22 mg/dL 15 Days - 11 Months: 4 - 17 mg/dL 1 - 9 Years: 9 - 22 mg/dL >/= 10 Years: 7 - 20 mg/dL
693	BCH BPH RHR
694	BCH BPH RHR	Chloride	0 - 29 Days: 98 - 113 mmol/L >/= 30 Days: 98 - 107 mmol/L
695	BCH BPH RHR
696	BCH BPH RHR	CO2	0 - 27 Days: 15 - 22 mmol/L 28 Days - 11 Months: 20 - 28 mmol/L >/= 1 Year: 20 - 30 mmol/L
697	BCH BPH RHR
698	BCH BPH RHR	Anion Gap	10 - 20
699	BCH BPH RHR
700	BCH BPH RHR	Creatinine	0 - 14 Days: 0.4 - 1.1 mg/dL 15 Days - 11 Months: 0.3 - 0.5 mg/dL 1 - 11 Years: 0.4 - 0.7 mg/dL 12 - 14 Years: 0.6 - 0.8 mg/dL 15 - 17 Years: Male: 0.7 - 1.1 mg/dL Female: 0.6 - 0.9 mg/dL >/= 18 Years: Male: 0.7 - 1.3 mg/dL Female: 0.6 - 1.1 mg/dL
701	BCH BPH RHR
702	BCH BPH RHR	GFR	< 60 mL/min/1.73 sq meter
703	BCH BPH RHR
704	BCH BPH RHR	Glucose	NICU Inpatient Locations: 51 - 60 mg/dL 0 - 23 Hours: 40 - 60 mg/dL 1 - 11 Months: 54 - 80 mg/dL >/= 1 Year: 70 - 99 mg/dL
705	BCH BPH RHR
706	BCH BPH RHR	Hematocrit	Male: 0 - 14 Days: 39.8 - 53.6 % 15 - 30 Days: 30.5 - 45.0 % 31 - 60 Days: 26.8 - 37.5 % 2 - 5 Months: 28.6 - 37.2 % 6 - 23 Months: 30.8 - 37.8 % 2 - 5 Years: 31.0 - 37.7 % 6 - 11 Years: 32.2 - 39.8 % 12 - 17 Years: 33.9 - 43.5 % >/= 18 Years: 39.4 - 51.6 % Female: 0 - 14 Days: 39.6 - 57.2 % 15 - 30 Days: 32.0 - 44.5 % 31 - 60 Days: 27.7 - 35.1 % 2 - 5 Months: 29.5 - 37.1 % 6 - 23 Months: 30.9 - 37.9 % 2 - 5 Years: 31.2 - 37.8 % 6 - 11 Years: 32.4 - 39.5 % 12 - 17 Years: 33.4 - 40.4 % >/= 18 Years: 35.6 - 47.3 %
707	BCH BPH RHR
708	BCH BPH RHR	Hemoglobin	Male: 0 - 14 Days: 13.9 - 19.1 g/dL 15 - 30 Days: 10.0 - 15.3 g/dL 31 - 60 Days: 8.9 - 12.7 g/dL 2 - 5 Months: 9.6 - 12.4 g/dL 6 - 23 Months: 10.1 - 12.5 g/dL 2 - 5 Years: 10.2 - 12.7 g/dL 6 - 11 Years: 10.7 - 13.4 g/dL 12 - 17 Years: 11.0 - 14.5 g/dL >/= 18 Years: 12.7 - 17.2 g/dL Female: 0 - 14 Days: 13.4 - 20.0 g/dL 15 - 30 Days: 10.8 - 14.6 g/dL 31 - 60 Days: 9.2 - 11.4 g/dL 2 - 5 Months: 9.9 - 12.4 g/dL 6 Months - 5 Years: 10.2 - 12.7 g/dL 6 - 11 Years: 10.6 - 13.2 g/dL 12 - 17 Years: 10.8 - 13.3 g/dL >/= 18 Years: 11.0 - 15.4 g/dL
709	BCH BPH RHR
710	BCH BPH RHR	Ionized Calcium	1.13 - 1.33 mmol/L
711	BCH BPH RHR
712	BCH BPH RHR	Potassium	0 - 27 Days: 3.7 - 5.9 mmol/L 28 Days - 1 Year: 4.1 - 5.3 mmol/L 2 - 17 Years: 3.4 - 4.7 mmol/L >/= 18 Years: 3.5 - 5.1 mmol/L
713	BCH BPH RHR
714	BCH BPH RHR	Sodium	0 - 26 Days: 133 - 146 mmol/L 27 Days - 1 Year: 139 - 146 mmol/L 2 - 17 Years: 138 - 146 mmol/L >/= 18 Years: 136 - 145 mmol/L
715	BCH BPH RHR
716	BCH BPH RHR	TCO2	0 - 27 Days: 15 - 22 mmol/L 28 Days - 1 Year: 20 - 28 mmol/L >/= 1 Year: 20 - 30 mmol/L
717	BCH BPH RHR
718	GMH GrMH HMH NGH OMH PWH	Troponin (Point of Care):	i-STAT: </= 0.08 ng/mL
719	GMH GrMH HMH NGH OMH PWH
720	Respiratory	RESPIRATORY (Blood Gas):	.
721	Respiratory	Prisma Health Baptist Columbia Respiratory Therapy Taylor at Marion Street Columbia, SC 29220	Prisma Health Baptist Parkridge Respiratory Therapy 400 Palmetto Health Parkway Columbia, SC 29212
722	Respiratory	Prisma Health Richland Respiratory Therapy 5 Richland Medical Park Drive Columbia, SC 29203	Prisma Health Tuomey Hospital Laboratory 129 North Washington Street Sumter, SC 29150
723
724	Respiratory	PROCEDURE:	REFERENCE:
725	Respiratory	Blood Gas:	.
726	Respiratory	Arterial:	.
727	Respiratory	pH	7.35 – 7.45
728	Respiratory	pCO2	35 – 45 mmHg
729	Respiratory	pO2	.
730	Respiratory	0 - 1 Year:	45 - 100 mmHg
731	Respiratory	1 - 150 Years:	80 - 100 mmHg
732	Respiratory	sO2 (Oxygen Sat)	96.0 – 100.0 %
733	Respiratory	HCO3 (Bicarb)	22.0 – 26.0 mmol/L
734	Respiratory	OxyHemoglobin	95.0 – 98.0 %
735	Respiratory	CarboxyHemoglobin	0.0 – 4.9 %
736	Respiratory	MetHemoglobin	0.0 – 3.00 %
737	Respiratory	.	.
738	Respiratory	Venous:	.
739	Respiratory	pH	7.32 – 7.42
740	Respiratory	pCO2	41 - 51 mmHg
741	Respiratory	pO2	30 - 50 mmHg
742	Respiratory	sO2 (Oxygen Sat)	70.0 – 85.0 %
743	Respiratory	HCO3 (Bicarb)
744	Respiratory	NICU/Newborn Inpatient Locations:	22.0 – 24.0 mmol/L
745	Respiratory	Adult:	22.0 - 26.0 mmol/L
746	Respiratory	OxyHemoglobin	70.0 – 85.0 %
747	Respiratory	CarboxyHemoglobin	0.0 – 4.9 %
748	Respiratory	MetHemoglobin	0.0 – 3.00 %
749	Respiratory	.	.
750	Respiratory	Capillary:	.
751	Respiratory	pH	7.30 – 7.45
752	Respiratory	pCO2	35 - 50 mmHg
753	Respiratory	pO2	45 - 55 mmHg
754	Respiratory	sO2 (Oxygen Sat)	92.0 – 100.0 %
755	Respiratory	HCO3 (Bicarb)	22.0 – 26.0 mmol/L
756	Respiratory	OxyHemoglobin	92.0 – 100.0 %
757	Respiratory	CarboxyHemoglobin	0.0 – 4.9 %
758	Respiratory	MetHemoglobin	0.0 – 3.00 %
759	Respiratory	.	.
760	Respiratory	Mixed Venous:	.
761	Respiratory	pH	7.32 – 7.45
762	Respiratory	pCO2	41 – 51 mmHg
763	Respiratory	pO2	35 - 54 mmHg
764	Respiratory	sO2 (Oxygen Sat)	70.0 – 85.0 %
765	Respiratory	HCO3 (Bicarb)
766	Respiratory	NICU/Newborn Inpatient Locations:	22.0 – 24.0 mmol/L
767	Respiratory	Adult:	22.0 - 26.0 mmol/L
768	Respiratory	OxyHemoglobin	70.0 – 85.0 %
769	Respiratory	CarboxyHemoglobin	0.0 – 4.9 %
770	Respiratory	MetHemoglobin	0.0 – 3.00 %
771	Respiratory	.	.
772	Respiratory	Cord Blood - Arterial:	.
773	Respiratory	pH	7.32 – 7.42
774	Respiratory	pCO2	41 - 51 mmHg
775	Respiratory	pO2	30 - 50 mmHg
776	Respiratory	sO2 (Oxygen Sat)	10.0 – 100.0 %
777	Respiratory	HCO3 (Bicarb)	22.0 – 24.0 mmol/L
778	Respiratory	.	.
779	Respiratory	Cord Blood - Venous:	.
780	Respiratory	pH	7.32 – 7.42
781	Respiratory	pCO2	41 - 51 mmHg
782	Respiratory	pO2	30 - 50 mmHg
783	Respiratory	sO2 (Oxygen Sat)	10.0 – 100.0 %
784	Respiratory	HCO3 (Bicarb)	22.0 – 24.0 mmol/L
785	Respiratory	.	.
786	Respiratory	Hematocrit:	.
787	Respiratory	NICU/Newborn	39.6 – 57.2 %
788	Respiratory	Adult	.
789	Respiratory	Female:	34.1 – 44.9 %
790	Respiratory	Male:	40.1 – 51.1 %
791	Respiratory	Hemoglobin	.
792	Respiratory	NICU/Newborn	13.4 – 20.0 g/dL
793	Respiratory	Adult	.
794	Respiratory	Female:	11.0 – 15.4 g/dL
795	Respiratory	Male:	12.7 – 17.2 g/dL
796	Respiratory	Sodium	.
797	Respiratory	NICU/Newborn	133 - 146 mmol/L
798	Respiratory	Adult	136 - 145 mmol/L
799	Respiratory	Potassium	.
800	Respiratory	NICU/Newborn	3.7 – 5.9 mmol/L
801	Respiratory	Adult	3.5 – 5.1 mmol/L
802	Respiratory	Chloride	.
803	Respiratory	NICU/Newborn	98 - 113 mmol/L
804	Respiratory	Adult	98 - 107 mmol/L
805	Respiratory	Ionized Calcium	1.13 – 1.33 mmol/L
806	Respiratory	Glucose	.
807	Respiratory	NICU	51 - 60 mg/dL
808	Respiratory	Newborn	40 - 60 mg/dL
809	Respiratory	Adult	70 - 99 mg/dL
810	Respiratory	Lactate	0.5 – 2.2 mmol/L